PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"28052619","The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma","Reig M, Boix L, Bruix J.","Liver Int. 2017 Jan;37 Suppl 1:136-139. doi: 10.1111/liv.13321.","Reig M","Liver Int","2017","2017/01/05","","","10.1111/liv.13321"
"28052621","Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)","Grossi G, Viganò M, Loglio A, Lampertico P.","Liver Int. 2017 Jan;37 Suppl 1:45-51. doi: 10.1111/liv.13291.","Grossi G","Liver Int","2017","2017/01/05","","","10.1111/liv.13291"
"28052626","Therapies in non-alcoholic steatohepatitis (NASH)","Oseini AM, Sanyal AJ.","Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):97-103. doi: 10.1111/liv.13302.","Oseini AM","Liver Int","2017","2017/01/05","PMC5492893","NIHMS828245","10.1111/liv.13302"
"28052627","From HCV To HBV Cure","Schinazi RF, Asselah T.","Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):73-80. doi: 10.1111/liv.13324.","Schinazi RF","Liver Int","2017","2017/01/05","PMC5217293","NIHMS832507","10.1111/liv.13324"
"28147363","Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials","Kudo M.","Oncology. 2017;92 Suppl 1:50-62. doi: 10.1159/000451016. Epub 2017 Feb 2.","Kudo M","Oncology","2017","2017/02/02","","","10.1159/000451016"
"28605745","Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma","Eggert T, Greten TF.","Digestion. 2017;96(1):1-4. doi: 10.1159/000464282. Epub 2017 Jun 13.","Eggert T","Digestion","2017","2017/06/13","PMC5548590","NIHMS856877","10.1159/000464282"
"29040995","Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma","Nishida N, Kudo M.","Dig Dis. 2017;35(6):618-622. doi: 10.1159/000480258. Epub 2017 Oct 17.","Nishida N","Dig Dis","2017","2017/10/18","","","10.1159/000480258"
"29258086","Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)","Kudo M, Arizumi T.","Oncology. 2017;93 Suppl 1:127-134. doi: 10.1159/000481243. Epub 2017 Dec 20.","Kudo M","Oncology","2017","2017/12/20","","","10.1159/000481243"
"29283332","Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma","Akhtar B, Muhammad F, Sharif A, Akhtar MF, Majeed W.","Crit Rev Eukaryot Gene Expr. 2017;27(4):373-385. doi: 10.1615/CritRevEukaryotGeneExpr.2017021006.","Akhtar B","Crit Rev Eukaryot Gene Expr","2017","2017/12/29","","","10.1615/CritRevEukaryotGeneExpr.2017021006"
"28045619","Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials","Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P.","J Clin Oncol. 2017 Feb 20;35(6):622-628. doi: 10.1200/JCO.2016.69.5197. Epub 2017 Jan 3.","Jackson R","J Clin Oncol","2017","2017/01/04","","","10.1200/JCO.2016.69.5197"
"28223446","Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action","Bril F, Cusi K.","Diabetes Care. 2017 Mar;40(3):419-430. doi: 10.2337/dc16-1787.","Bril F","Diabetes Care","2017","2017/02/23","","","10.2337/dc16-1787"
"28267205","External beam radiotherapy for unresectable hepatocellular carcinoma","Abdel-Rahman O, Elsayed Z.","Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.","Abdel-Rahman O","Cochrane Database Syst Rev","2017","2017/03/08","PMC6464365","","10.1002/14651858.CD011314.pub2"
"28122204","To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes","Dou Y, Hynynen K, Allen C.","J Control Release. 2017 Mar 10;249:63-73. doi: 10.1016/j.jconrel.2017.01.025. Epub 2017 Jan 22.","Dou Y","J Control Release","2017","2017/01/26","","","10.1016/j.jconrel.2017.01.025"
"28281295","Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis","Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS.","Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2.","Roccarina D","Cochrane Database Syst Rev","2017","2017/03/11","PMC6464331","","10.1002/14651858.CD011649.pub2"
"28351116","Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis","Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS.","Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.","Majumdar A","Cochrane Database Syst Rev","2017","2017/03/29","PMC6464490","","10.1002/14651858.CD011650.pub2"
"28299645","New concepts in embolotherapy of HCC","Pesapane F, Nezami N, Patella F, Geschwind JF.","Med Oncol. 2017 Apr;34(4):58. doi: 10.1007/s12032-017-0917-2. Epub 2017 Mar 16.","Pesapane F","Med Oncol","2017","2017/03/17","","","10.1007/s12032-017-0917-2"
"28428725","Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma","Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J.","World J Gastroenterol. 2017 Apr 7;23(13):2448-2452. doi: 10.3748/wjg.v23.i13.2448.","Rimassa L","World J Gastroenterol","2017","2017/04/22","PMC5385412","","10.3748/wjg.v23.i13.2448"
"28425410","Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center","Palmer WC, Lee D, Burns J, Croome K, Rosser B, Patel T, Keaveny AP, Pungpapong S, Satyanarayana R, Yataco M, Nakhleh R, Musto KR, Canabal AM, Turnage AK, Hodge DO, Nguyen JH, Harnois DM.","Ann Hepatol. 2017 May-Jun;16(3):402-411. doi: 10.5604/16652681.1235483.","Palmer WC","Ann Hepatol","2017","2017/04/21","","","10.5604/16652681.1235483"
"28514316","New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis","Li K, Wang HT, He YK, Guo T.","Medicine (Baltimore). 2017 May;96(20):e6950. doi: 10.1097/MD.0000000000006950.","Li K","Medicine (Baltimore)","2017","2017/05/18","PMC5440153","","10.1097/MD.0000000000006950"
"28600578","Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis","Zhao J, Li D, Shi Y, Shi F, Feng C, Li W, Tao M, Liang R.","Ann Acad Med Singap. 2017 May;46(5):174-184.","Zhao J","Ann Acad Med Singap","2017","2017/06/11","","",""
"28715649","Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature","Mamdani H, Wu H, O'Neil BH, Sehdev A.","Discov Med. 2017 May;23(128):331-336.","Mamdani H","Discov Med","2017","2017/07/18","","",""
"28412743","Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review","Cai XR, Li X, Lin JX, Wang TT, Dong M, Chen ZH, Jia CC, Hong YF, Lin Q, Wu XY.","Oncotarget. 2017 May 9;8(19):31318-31328. doi: 10.18632/oncotarget.15454.","Cai XR","Oncotarget","2017","2017/04/17","PMC5458210","","10.18632/oncotarget.15454"
"28170115","Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis","Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK.","Hepatology. 2017 Jun;65(6):1979-1990. doi: 10.1002/hep.29098. Epub 2017 Apr 28.","Lee MW","Hepatology","2017","2017/02/08","","","10.1002/hep.29098"
"28198177","Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena","Ferri J, Dockx Y, Vonghia L, Papadimitriou K, Rasschaert M, Francque S, Peeters M, Rolfo C.","Minerva Chir. 2017 Jun;72(3):206-218. doi: 10.23736/S0026-4733.17.07311-4. Epub 2017 Feb 14.","Ferri J","Minerva Chir","2017","2017/02/16","","","10.23736/S0026-4733.17.07311-4"
"28276833","Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis","Liao M, Zhu Z, Wang H, Huang J.","Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):624-634. doi: 10.1080/00365521.2017.1292365. Epub 2017 Feb 22.","Liao M","Scand J Gastroenterol","2017","2017/03/10","","","10.1080/00365521.2017.1292365"
"28295992","Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis","Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, Mallat A, Launoy G, Laurent A.","Liver Transpl. 2017 Jun;23(6):836-844. doi: 10.1002/lt.24758.","Menahem B","Liver Transpl","2017","2017/03/16","","","10.1002/lt.24758"
"28349301","Effect of traditional Chinese medicine combined with Western therapy on primary hepatic carcinoma: a systematic review with meta-analysis","Ma L, Wang B, Long Y, Li H.","Front Med. 2017 Jun;11(2):191-202. doi: 10.1007/s11684-017-0512-0. Epub 2017 Mar 27.","Ma L","Front Med","2017","2017/03/29","","","10.1007/s11684-017-0512-0"
"28589772","Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017","Sacco R, Mirabile A, Giacomelli L, Bresci G, Attardo S, Cabibbo G.","Future Oncol. 2017 Jun;13(15):1297-1300. doi: 10.2217/fon-2017-0133. Epub 2017 Jun 7.","Sacco R","Future Oncol","2017","2017/06/08","","","10.2217/fon-2017-0133"
"28659623","A systematic review and meta-analysis of traditional insect Chinese medicines combined chemotherapy for non-surgical hepatocellular carcinoma therapy","Shi Z, Song T, Wan Y, Xie J, Yan Y, Shi K, Du Y, Shang L.","Sci Rep. 2017 Jun 28;7(1):4355. doi: 10.1038/s41598-017-04351-y.","Shi Z","Sci Rep","2017","2017/06/30","PMC5489479","","10.1038/s41598-017-04351-y"
"28257902","Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR.","J Hepatol. 2017 Jul;67(1):92-99. doi: 10.1016/j.jhep.2017.02.022. Epub 2017 Feb 28.","Sapisochin G","J Hepatol","2017","2017/03/05","","","10.1016/j.jhep.2017.02.022"
"28580808","Regorafenib for the treatment of unresectable hepatocellular carcinoma","Rimassa L, Pressiani T, Personeni N, Santoro A.","Expert Rev Anticancer Ther. 2017 Jul;17(7):567-576. doi: 10.1080/14737140.2017.1338955. Epub 2017 Jun 9.","Rimassa L","Expert Rev Anticancer Ther","2017","2017/06/06","","","10.1080/14737140.2017.1338955"
"28412170","Lipid Nanoparticle Systems for Enabling Gene Therapies","Cullis PR, Hope MJ.","Mol Ther. 2017 Jul 5;25(7):1467-1475. doi: 10.1016/j.ymthe.2017.03.013. Epub 2017 Apr 13.","Cullis PR","Mol Ther","2017","2017/04/17","PMC5498813","","10.1016/j.ymthe.2017.03.013"
"28648803","Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.","Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23.","Meyer T","Lancet Gastroenterol Hepatol","2017","2017/06/27","","","10.1016/S2468-1253(17)30156-5"
"29036035","The treatment path in hepatocellular carcinoma","El-Serag HB, Zhu AX, Johnson MS.","Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):1-20.","El-Serag HB","Clin Adv Hematol Oncol","2017","2017/10/17","","",""
"28299819","Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: A meta-analysis","Lv XH, Wang CH, Xie Y.","J Gastroenterol Hepatol. 2017 Sep;32(9):1540-1547. doi: 10.1111/jgh.13789.","Lv XH","J Gastroenterol Hepatol","2017","2017/03/17","","","10.1111/jgh.13789"
"28693355","Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial","Tovoli F, Lorenzo S, Barbera MA, Garajova I, Frega G, Palloni A, Pantaleo MA, Biasco G, Brandi G.","Future Oncol. 2017 Sep;13(21):1893-1905. doi: 10.2217/fon-2017-0166. Epub 2017 Jul 11.","Tovoli F","Future Oncol","2017","2017/07/12","","","10.2217/fon-2017-0166"
"28826591","Individualised adaptive radiotherapy in liver cancer","Das M.","Lancet Oncol. 2017 Sep;18(9):e520. doi: 10.1016/S1470-2045(17)30626-5. Epub 2017 Aug 17.","Das M","Lancet Oncol","2017","2017/08/23","","","10.1016/S1470-2045(17)30626-5"
"28934265","Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials","Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D.","PLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.0184597. eCollection 2017.","Katsanos K","PLoS One","2017","2017/09/22","PMC5608206","","10.1371/journal.pone.0184597"
"28545937","Treatment of NAFLD with diet, physical activity and exercise","Romero-Gómez M, Zelber-Sagi S, Trenell M.","J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016. Epub 2017 May 23.","Romero-Gómez M","J Hepatol","2017","2017/05/27","","","10.1016/j.jhep.2017.05.016"
"28766967","Regorafenib as treatment for patients with advanced hepatocellular cancer","Thillai K, Srikandarajah K, Ross P.","Future Oncol. 2017 Oct;13(25):2223-2232. doi: 10.2217/fon-2017-0204. Epub 2017 Aug 2.","Thillai K","Future Oncol","2017","2017/08/03","","","10.2217/fon-2017-0204"
"28893090","An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma","Raoul JL, Gilabert M, Adhoute X, Edeline J.","Expert Opin Pharmacother. 2017 Oct;18(14):1467-1476. doi: 10.1080/14656566.2017.1378346. Epub 2017 Sep 14.","Raoul JL","Expert Opin Pharmacother","2017","2017/09/13","","","10.1080/14656566.2017.1378346"
"28923223","An Update on Randomized Clinical Trials in Hepatocellular Carcinoma","Sim HW, Knox J, Dawson LA.","Surg Oncol Clin N Am. 2017 Oct;26(4):647-666. doi: 10.1016/j.soc.2017.05.006. Epub 2017 Aug 4.","Sim HW","Surg Oncol Clin N Am","2017","2017/09/20","","","10.1016/j.soc.2017.05.006"
"28976206","The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma","Chow PK, Gandhi M, Gebski V.","Future Oncol. 2017 Oct;13(25):2213-2216. doi: 10.2217/fon-2017-0395. Epub 2017 Oct 4.","Chow PK","Future Oncol","2017","2017/10/05","","","10.2217/fon-2017-0395"
"28758319","Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres","Wang EA, Stein JP, Bellavia RJ, Broadwell SR.","Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.","Wang EA","Int J Clin Pract","2017","2017/08/01","","","10.1111/ijcp.12972"
"28972597","PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC","Parikh ND.","Am J Gastroenterol. 2017 Nov;112(11):1632-1633. doi: 10.1038/ajg.2017.366. Epub 2017 Oct 3.","Parikh ND","Am J Gastroenterol","2017","2017/10/04","","","10.1038/ajg.2017.366"
"29059128","The 2017 Transplantation Awards: Recognizing a Landmark Clinical Trial and a Basic Science Discovery With Far-Reaching Implications","Grey ST, Issa F.","Transplantation. 2017 Nov;101(11):2655-2656. doi: 10.1097/TP.0000000000001949.","Grey ST","Transplantation","2017","2017/10/24","","","10.1097/TP.0000000000001949"
"28945955","Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis","Lim C, Shinkawa H, Hasegawa K, Bhangui P, Salloum C, Gomez Gavara C, Lahat E, Omichi K, Arita J, Sakamoto Y, Compagnon P, Feray C, Kokudo N, Azoulay D.","Liver Transpl. 2017 Dec;23(12):1553-1563. doi: 10.1002/lt.24952.","Lim C","Liver Transpl","2017","2017/09/26","","","10.1002/lt.24952"
"29054475","New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies","Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG.","Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):564-570. doi: 10.1016/j.bbcan.2017.10.002. Epub 2017 Oct 17.","Niu L","Biochim Biophys Acta Rev Cancer","2017","2017/10/22","","","10.1016/j.bbcan.2017.10.002"
"28806477","Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis","de Haas RJ, Lim C, Bhangui P, Salloum C, Compagnon P, Feray C, Calderaro J, Luciani A, Azoulay D.","Hepatology. 2018 Jan;67(1):204-215. doi: 10.1002/hep.29468. Epub 2017 Nov 15.","de Haas RJ","Hepatology","2018","2017/08/15","","","10.1002/hep.29468"
"29050983","Precision diagnosis and treatment of liver cancer in China","Fu J, Wang H.","Cancer Lett. 2018 Jan 1;412:283-288. doi: 10.1016/j.canlet.2017.10.008. Epub 2017 Oct 16.","Fu J","Cancer Lett","2018","2017/10/21","","","10.1016/j.canlet.2017.10.008"
"29360073","Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives","Mazzolini GD, Malvicini M.","Medicina (B Aires). 2018;78(1):29-32.","Mazzolini GD","Medicina (B Aires)","2018","2018/01/24","","",""
"29397186","Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies","McNamara MG.","Curr Probl Cancer. 2018 Jan-Feb;42(1):8-11. doi: 10.1016/j.currproblcancer.2017.12.003. Epub 2018 Jan 5.","McNamara MG","Curr Probl Cancer","2018","2018/02/05","","","10.1016/j.currproblcancer.2017.12.003"
"29569657","Regorafenib for the treatment of hepatocellular carcinoma","Tovoli F, Granito A, De Lorenzo S, Bolondi L.","Drugs Today (Barc). 2018 Jan;54(1):5-13. doi: 10.1358/dot.2018.54.1.2736667.","Tovoli F","Drugs Today (Barc)","2018","2018/03/24","","","10.1358/dot.2018.54.1.2736667"
"29705790","Immunotherapy of Hepatocellular Carcinoma","Heinrich B, Czauderna C, Marquardt JU.","Oncol Res Treat. 2018;41(5):292-297. doi: 10.1159/000488916. Epub 2018 Apr 20.","Heinrich B","Oncol Res Treat","2018","2018/04/30","","","10.1159/000488916"
"29253194","Chemotherapy for hepatocellular carcinoma: current status and future perspectives","Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J.","Jpn J Clin Oncol. 2018 Feb 1;48(2):103-114. doi: 10.1093/jjco/hyx180.","Ikeda M","Jpn J Clin Oncol","2018","2017/12/19","","","10.1093/jjco/hyx180"
"29427491","Managing hepatitis C in patients with the complications of cirrhosis","Mücke MM, Mücke VT, Lange CM, Zeuzem S.","Liver Int. 2018 Feb;38 Suppl 1:14-20. doi: 10.1111/liv.13636.","Mücke MM","Liver Int","2018","2018/02/11","","","10.1111/liv.13636"
"28482112","A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers","Tayob N, Stingo F, Do KA, Lok ASF, Feng Z.","Biometrics. 2018 Mar;74(1):249-259. doi: 10.1111/biom.12717. Epub 2017 May 8.","Tayob N","Biometrics","2018","2017/05/09","PMC5677596","NIHMS870768","10.1111/biom.12717"
"29619621","Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response","Kanda T, Matsuoka S, Moriyama M.","Hepatol Int. 2018 Mar;12(2):90-93. doi: 10.1007/s12072-018-9862-1. Epub 2018 Apr 4.","Kanda T","Hepatol Int","2018","2018/04/06","","","10.1007/s12072-018-9862-1"
"29433849","Lenvatinib: can a non-inferiority trial change clinical practice?","Reig M, Bruix J.","Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3. Epub 2018 Feb 9.","Reig M","Lancet","2018","2018/02/14","","","10.1016/S0140-6736(18)30208-3"
"29138342","Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes","Iñarrairaegui M, Melero I, Sangro B.","Clin Cancer Res. 2018 Apr 1;24(7):1518-1524. doi: 10.1158/1078-0432.CCR-17-0289. Epub 2017 Nov 14.","Iñarrairaegui M","Clin Cancer Res","2018","2017/11/16","","","10.1158/1078-0432.CCR-17-0289"
"29272034","Intention-to-treat survival benefit in liver transplantation: Comments on Lai et al","Winter A, Daurès JP, Landais P.","Hepatology. 2018 Apr;67(4):1638-1639. doi: 10.1002/hep.29755. Epub 2018 Feb 27.","Winter A","Hepatology","2018","2017/12/23","","","10.1002/hep.29755"
"29427028","2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)","Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, Hiyama E, Czauderna P, Roebuck DJ, Tiao GM.","Pediatr Radiol. 2018 Apr;48(4):536-554. doi: 10.1007/s00247-018-4078-z. Epub 2018 Feb 9.","Towbin AJ","Pediatr Radiol","2018","2018/02/11","","","10.1007/s00247-018-4078-z"
"29533189","Treatment of advanced hepatocellular carcinoma: beyond sorafenib","Meyer T.","Lancet Gastroenterol Hepatol. 2018 Apr;3(4):218-220. doi: 10.1016/S2468-1253(17)30255-8. Epub 2018 Mar 7.","Meyer T","Lancet Gastroenterol Hepatol","2018","2018/03/14","","","10.1016/S2468-1253(17)30255-8"
"29135366","Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis","Xu XL, Liu XD, Liang M, Luo BM.","Radiology. 2018 May;287(2):461-472. doi: 10.1148/radiol.2017162756. Epub 2017 Nov 13.","Xu XL","Radiology","2018","2017/11/15","","","10.1148/radiol.2017162756"
"29576417","TACE plus external beam radiotherapy in liver cancer","Das M.","Lancet Oncol. 2018 May;19(5):e231. doi: 10.1016/S1470-2045(18)30218-3. Epub 2018 Mar 23.","Das M","Lancet Oncol","2018","2018/03/27","","","10.1016/S1470-2045(18)30218-3"
"29668405","Radiofrequency Ablation versus Resection for Small Hepatocellular Carcinoma: Are Randomized Controlled Trials Still Needed?","Crocetti L.","Radiology. 2018 May;287(2):473-475. doi: 10.1148/radiol.2018172822.","Crocetti L","Radiology","2018","2018/04/19","","","10.1148/radiol.2018172822"
"29871016","Noninferiority Clinical Trials: The Good, the Bad, and the Ugly","Lesaffre E.","Semin Liver Dis. 2018 May;38(2):97-102. doi: 10.1055/s-0038-1655777. Epub 2018 Jun 5.","Lesaffre E","Semin Liver Dis","2018","2018/06/06","","","10.1055/s-0038-1655777"
"29843754","Immune checkpoint therapy in liver cancer","Xu F, Jin T, Zhu Y, Dai C.","J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4.","Xu F","J Exp Clin Cancer Res","2018","2018/05/31","PMC5975687","","10.1186/s13046-018-0777-4"
"28871342","A systematic review of publications on charged particle therapy for hepatocellular carcinoma","Igaki H, Mizumoto M, Okumura T, Hasegawa K, Kokudo N, Sakurai H.","Int J Clin Oncol. 2018 Jun;23(3):423-433. doi: 10.1007/s10147-017-1190-2. Epub 2017 Sep 4.","Igaki H","Int J Clin Oncol","2018","2017/09/06","","","10.1007/s10147-017-1190-2"
"29119705","On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis","Wu S, Kong Y, Piao H, Jiang W, Xie W, Chen Y, Lu L, Ma A, Xie S, Ding H, Shang J, Zhang X, Feng B, Han T, Xu X, Huo L, Cheng J, Li H, Wu X, Zhou J, Sun Y, Ou X, Zhang H, You H, Jia J.","Liver Int. 2018 Jun;38(6):1045-1054. doi: 10.1111/liv.13623. Epub 2017 Nov 29.","Wu S","Liver Int","2018","2017/11/10","","","10.1111/liv.13623"
"29631810","Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group.","Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.","Kudo M","Lancet Gastroenterol Hepatol","2018","2018/04/11","","","10.1016/S2468-1253(18)30078-5"
"29807383","[Hepatocellular Carcinoma: New multimodal therapy concepts]","Schultheiß M, Bettinger D, Fichtner-Feigl S, Thimme R.","Dtsch Med Wochenschr. 2018 Jun;143(11):815-819. doi: 10.1055/s-0043-124158. Epub 2018 May 28.","Schultheiß M","Dtsch Med Wochenschr","2018","2018/05/29","","","10.1055/s-0043-124158"
"29974040","Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery","Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y.","Can J Gastroenterol Hepatol. 2018 Jun 3;2018:4756147. doi: 10.1155/2018/4756147. eCollection 2018.","Shiina S","Can J Gastroenterol Hepatol","2018","2018/07/06","PMC6008833","","10.1155/2018/4756147"
"28682469","A(3) Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy","Jacobson KA, Merighi S, Varani K, Borea PA, Baraldi S, Aghazadeh Tabrizi M, Romagnoli R, Baraldi PG, Ciancetta A, Tosh DK, Gao ZG, Gessi S.","Med Res Rev. 2018 Jul;38(4):1031-1072. doi: 10.1002/med.21456. Epub 2017 Jul 6.","Jacobson KA","Med Res Rev","2018","2017/07/07","PMC5756520","NIHMS924970","10.1002/med.21456"
"29505843","The role of molecular enrichment on future therapies in hepatocellular carcinoma","Nault JC, Galle PR, Marquardt JU.","J Hepatol. 2018 Jul;69(1):237-247. doi: 10.1016/j.jhep.2018.02.016. Epub 2018 Mar 2.","Nault JC","J Hepatol","2018","2018/03/06","","","10.1016/j.jhep.2018.02.016"
"29783126","Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond","Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.","Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26.","Raoul JL","Cancer Treat Rev","2018","2018/05/22","","","10.1016/j.ctrv.2018.05.006"
"29653122","New trials and results in systemic treatment of HCC","Reig M, da Fonseca LG, Faivre S.","J Hepatol. 2018 Aug;69(2):525-533. doi: 10.1016/j.jhep.2018.03.028. Epub 2018 Apr 11.","Reig M","J Hepatol","2018","2018/04/14","","","10.1016/j.jhep.2018.03.028"
"29783903","Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma","Baxter MA, Glen H, Evans TR.","Future Oncol. 2018 Aug;14(20):2021-2029. doi: 10.2217/fon-2017-0689. Epub 2018 May 22.","Baxter MA","Future Oncol","2018","2018/05/23","","","10.2217/fon-2017-0689"
"29900755","Exploring the role of oncolytic viruses in hepatobiliary cancers","Tenneti P, Borad MJ, Babiker HM.","Immunotherapy. 2018 Aug;10(11):971-986. doi: 10.2217/imt-2018-0048. Epub 2018 Jun 14.","Tenneti P","Immunotherapy","2018","2018/06/15","","","10.2217/imt-2018-0048"
"29983345","Refametinib in RAS-mutated hepatocellular cancer","Das M.","Lancet Oncol. 2018 Aug;19(8):e389. doi: 10.1016/S1470-2045(18)30505-9. Epub 2018 Jul 5.","Das M","Lancet Oncol","2018","2018/07/10","","","10.1016/S1470-2045(18)30505-9"
"30134489","Salvage-Leber-Transplantation","","Zentralbl Chir. 2018 Aug;143(4):343. doi: 10.1055/a-0655-2840. Epub 2018 Aug 22.","","Zentralbl Chir","2018","2018/08/23","","","10.1055/a-0655-2840"
"30159302","The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma","Abdel-Rahman O, Cheung WY.","Can J Gastroenterol Hepatol. 2018 Aug 7;2018:4763832. doi: 10.1155/2018/4763832. eCollection 2018.","Abdel-Rahman O","Can J Gastroenterol Hepatol","2018","2018/08/31","PMC6106970","","10.1155/2018/4763832"
"29935174","Strategies for the treatment of HBV/HDV","Krause A, Haberkorn U, Mier W.","Eur J Pharmacol. 2018 Aug 15;833:379-391. doi: 10.1016/j.ejphar.2018.06.030. Epub 2018 Jun 21.","Krause A","Eur J Pharmacol","2018","2018/06/24","","","10.1016/j.ejphar.2018.06.030"
"30139041","Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach","Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D.","Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2043-2055. doi: 10.22034/APJCP.2018.19.8.2043.","Yang W","Asian Pac J Cancer Prev","2018","2018/08/25","PMC6171403","","10.22034/APJCP.2018.19.8.2043"
"29663837","Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials","Harding JJ.","Future Oncol. 2018 Sep;14(22):2293-2302. doi: 10.2217/fon-2018-0008. Epub 2018 Apr 17.","Harding JJ","Future Oncol","2018","2018/04/18","PMC7444624","","10.2217/fon-2018-0008"
"29806062","Hepatocellular Carcinoma: Review of Targeted and Immune Therapies","da Motta Girardi D, Correa TS, Crosara Teixeira M, Dos Santos Fernandes G.","J Gastrointest Cancer. 2018 Sep;49(3):227-236. doi: 10.1007/s12029-018-0121-4.","da Motta Girardi D","J Gastrointest Cancer","2018","2018/05/29","","","10.1007/s12029-018-0121-4"
"30006024","The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial","Proeschold-Bell RJ, Evon DM, Makarushka C, Wong JB, Datta SK, Yao J, Patkar AA, Mannelli P, Hodge T, Naggie S, Wilder JM, Fried MW, Niedzwiecki D, Muir AJ.","Contemp Clin Trials. 2018 Sep;72:73-85. doi: 10.1016/j.cct.2018.07.003. Epub 2018 Jul 10.","Proeschold-Bell RJ","Contemp Clin Trials","2018","2018/07/15","PMC6711183","NIHMS1044408","10.1016/j.cct.2018.07.003"
"30271119","Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials","Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, Lou L.","Drug Des Devel Ther. 2018 Sep 18;12:3043-3049. doi: 10.2147/DDDT.S151241. eCollection 2018.","Li X","Drug Des Devel Ther","2018","2018/10/02","PMC6151100","","10.2147/DDDT.S151241"
"30271080","Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?","Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A.","World J Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152.","Marisi G","World J Gastroenterol","2018","2018/10/02","PMC6158485","","10.3748/wjg.v24.i36.4152"
"30118333","Testing for AFP in combination with ultrasound improves early liver cancer detection","Tzartzeva K, Singal AG.","Expert Rev Gastroenterol Hepatol. 2018 Oct;12(10):947-949. doi: 10.1080/17474124.2018.1512855. Epub 2018 Aug 21.","Tzartzeva K","Expert Rev Gastroenterol Hepatol","2018","2018/08/18","","","10.1080/17474124.2018.1512855"
"30398482","An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib","Ielasi L, Sansone V, Granito A, Benevento F, De Lorenzo S, Tovoli F.","Drugs Today (Barc). 2018 Oct;54(10):615-627. doi: 10.1358/dot.2018.54.10.2880176.","Ielasi L","Drugs Today (Barc)","2018","2018/11/07","","","10.1358/dot.2018.54.10.2880176"
"30410942","Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma","Degroote H, Van Dierendonck A, Geerts A, Van Vlierberghe H, Devisscher L.","J Immunol Res. 2018 Oct 16;2018:7819520. doi: 10.1155/2018/7819520. eCollection 2018.","Degroote H","J Immunol Res","2018","2018/11/10","PMC6206557","","10.1155/2018/7819520"
"29953255","Liver chemoembolization of hepatocellular carcinoma using TANDEM(®) microspheres","Delicque J, Guiu B, Boulin M, Schwanz H, Piron L, Cassinotto C.","Future Oncol. 2018 Nov;14(26):2761-2772. doi: 10.2217/fon-2018-0237. Epub 2018 Jun 28.","Delicque J","Future Oncol","2018","2018/06/29","","","10.2217/fon-2018-0237"
"30357775","Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy","Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C.","Semin Liver Dis. 2018 Nov;38(4):379-388. doi: 10.1055/s-0038-1673621. Epub 2018 Oct 24.","Lin YY","Semin Liver Dis","2018","2018/10/26","","","10.1055/s-0038-1673621"
"30217745","Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma","Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, Ursic-Bedoya J, Pageaux GP, Mariano-Goulart D, Aho S, Guiu B.","J Vasc Interv Radiol. 2018 Dec;29(12):1662-1670.e4. doi: 10.1016/j.jvir.2018.07.006. Epub 2018 Sep 11.","Allimant C","J Vasc Interv Radiol","2018","2018/09/16","","","10.1016/j.jvir.2018.07.006"
"30304963","Nivolumab for the treatment of hepatocellular carcinoma","Finkelmeier F, Waidmann O, Trojan J.","Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22.","Finkelmeier F","Expert Rev Anticancer Ther","2018","2018/10/12","","","10.1080/14737140.2018.1535315"
"30384012","Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis","McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E.","Eur J Cancer. 2018 Dec;105:1-9. doi: 10.1016/j.ejca.2018.09.031. Epub 2018 Oct 29.","McNamara MG","Eur J Cancer","2018","2018/11/02","","","10.1016/j.ejca.2018.09.031"
"30687734","Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres","Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N.","Biomed Res Int. 2018 Dec 31;2018:1435302. doi: 10.1155/2018/1435302. eCollection 2018.","Bouvry C","Biomed Res Int","2018","2019/01/29","PMC6330886","","10.1155/2018/1435302"
"31092758","[Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma]","Watanabe T, Koyama N.","Nihon Yakurigaku Zasshi. 2019;153(5):242-248. doi: 10.1254/fpj.153.242.","Watanabe T","Nihon Yakurigaku Zasshi","2019","2019/05/17","","","10.1254/fpj.153.242"
"31099615","Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers","Grieb BC, Goff LW, Goyal L, Denlinger CS.","Am Soc Clin Oncol Educ Book. 2019 Jan;39:248-260. doi: 10.1200/EDBK_237555. Epub 2019 May 17.","Grieb BC","Am Soc Clin Oncol Educ Book","2019","2019/05/18","","","10.1200/EDBK_237555"
"31327798","Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma","Yao X, Wang L, Gao J.","Biosci Trends. 2019;13(3):282-283. doi: 10.5582/bst.2019.01161.","Yao X","Biosci Trends","2019","2019/07/23","","","10.5582/bst.2019.01161"
"30276959","Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: The impact of pre-existing diabetes mellitus","Li Z, Gao Z, Xiang J, Zhou J, Yan S, Hu Z.","Liver Int. 2019 Feb;39(2):361-370. doi: 10.1111/liv.13982. Epub 2018 Oct 24.","Li Z","Liver Int","2019","2018/10/03","","","10.1111/liv.13982"
"30317696","New Systemic Treatments in Advanced Hepatocellular Carcinoma","Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M.","Liver Transpl. 2019 Feb;25(2):311-322. doi: 10.1002/lt.25354.","Sanduzzi-Zamparelli M","Liver Transpl","2019","2018/10/15","","","10.1002/lt.25354"
"30659408","Adoptive cell transfer therapy for hepatocellular carcinoma","Zhang R, Zhang Z, Liu Z, Wei D, Wu X, Bian H, Chen Z.","Front Med. 2019 Feb;13(1):3-11. doi: 10.1007/s11684-019-0684-x. Epub 2019 Jan 18.","Zhang R","Front Med","2019","2019/01/20","","","10.1007/s11684-019-0684-x"
"30767164","Cabozantinib: A Review in Advanced Hepatocellular Carcinoma","Deeks ED.","Target Oncol. 2019 Feb;14(1):107-113. doi: 10.1007/s11523-019-00622-y.","Deeks ED","Target Oncol","2019","2019/02/16","","","10.1007/s11523-019-00622-y"
"30819826","Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges","Liu X, Qin S.","Oncologist. 2019 Feb;24(Suppl 1):S3-S10. doi: 10.1634/theoncologist.2019-IO-S1-s01.","Liu X","Oncologist","2019","2019/03/02","PMC6394775","","10.1634/theoncologist.2019-IO-S1-s01"
"30776082","Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults","Lu L, Zeng J, Wen Z, Tang C, Xu N.","Cochrane Database Syst Rev. 2019 Feb 16;2(2):CD012244. doi: 10.1002/14651858.CD012244.pub2.","Lu L","Cochrane Database Syst Rev","2019","2019/02/19","PMC6378926","","10.1002/14651858.CD012244.pub2"
"30809080","Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond","Kudo M.","World J Gastroenterol. 2019 Feb 21;25(7):789-807. doi: 10.3748/wjg.v25.i7.789.","Kudo M","World J Gastroenterol","2019","2019/02/28","PMC6385008","","10.3748/wjg.v25.i7.789"
"30644314","Ramucirumab and its use in the treatment of hepatocellular carcinoma","Turkes F, Chau I.","Future Oncol. 2019 Mar;15(9):979-988. doi: 10.2217/fon-2018-0822. Epub 2019 Jan 15.","Turkes F","Future Oncol","2019","2019/01/16","","","10.2217/fon-2018-0822"
"30922256","Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies","He L, Deng H, Lei J, Yi F, Li J, Fan X, Wei Y, Xu J, Zhang W.","BMC Cancer. 2019 Mar 28;19(1):276. doi: 10.1186/s12885-019-5487-6.","He L","BMC Cancer","2019","2019/03/30","PMC6437948","","10.1186/s12885-019-5487-6"
"29672442","More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma","Hogen R, Lo M, DiNorcia J, Ji L, Genyk Y, Sher L, Dhanireddy K.","Transplantation. 2019 Apr;103(4):747-754. doi: 10.1097/TP.0000000000002248.","Hogen R","Transplantation","2019","2018/04/20","","","10.1097/TP.0000000000002248"
"30575632","Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","Bakouny Z, Assi T, El Rassy E, Nasr F.","J Clin Gastroenterol. 2019 Apr;53(4):251-261. doi: 10.1097/MCG.0000000000001160.","Bakouny Z","J Clin Gastroenterol","2019","2018/12/22","","","10.1097/MCG.0000000000001160"
"30630009","Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation","Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, Ghanekar A, Lilly L, Cattral M, Galvin Z, Selzner M, Bhat M, Selzner N, McGilvray I, Greig PD, Grant DR, Sapisochin G.","J Hepatol. 2019 Apr;70(4):666-673. doi: 10.1016/j.jhep.2018.12.029. Epub 2019 Jan 8.","Goldaracena N","J Hepatol","2019","2019/01/11","","","10.1016/j.jhep.2018.12.029"
"30830522","Design and Endpoints of Clinical Trials, Current and Future","Sherman M.","Dig Dis Sci. 2019 Apr;64(4):1050-1057. doi: 10.1007/s10620-019-05541-6.","Sherman M","Dig Dis Sci","2019","2019/03/05","","","10.1007/s10620-019-05541-6"
"30939138","A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome","Amin S, Rattner J, Keramati MR, Farshidfar F, McNamara MG, Knox JJ, Kopciuk K, Vogel HJ, Bathe OF.","PLoS One. 2019 Apr 2;14(4):e0213942. doi: 10.1371/journal.pone.0213942. eCollection 2019.","Amin S","PLoS One","2019","2019/04/03","PMC6445409","","10.1371/journal.pone.0213942"
"31036040","All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial","Shi J, Sun J, Liu C, Chai Z, Wang N, Zhang H, Cheng S.","Trials. 2019 Apr 29;20(1):245. doi: 10.1186/s13063-019-3349-9.","Shi J","Trials","2019","2019/05/01","PMC6489221","","10.1186/s13063-019-3349-9"
"30660733","Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis","Kaplan DE, Serper MA, Mehta R, Fox R, John B, Aytaman A, Baytarian M, Hunt K, Albrecht J, Njei B, Taddei TH; VOCAL Study Group.","Gastroenterology. 2019 May;156(6):1693-1706.e12. doi: 10.1053/j.gastro.2019.01.026. Epub 2019 Jan 18.","Kaplan DE","Gastroenterology","2019","2019/01/21","","","10.1053/j.gastro.2019.01.026"
"30737669","Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses","Wong TCL, Ng KKC, Fung JYY, Chan AAC, Cheung TT, Chok KSH, Dai JWC, Lo CM.","Ann Surg Oncol. 2019 May;26(5):1454-1462. doi: 10.1245/s10434-019-07206-0. Epub 2019 Feb 8.","Wong TCL","Ann Surg Oncol","2019","2019/02/10","","","10.1245/s10434-019-07206-0"
"30738047","Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma","Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J.","Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.","Teufel M","Gastroenterology","2019","2019/02/10","","","10.1053/j.gastro.2019.01.261"
"31131841","Lenvatinib mesylate to treat hepatocellular carcinoma","Ielasi L, Tovoli F, Piscaglia F.","Drugs Today (Barc). 2019 May;55(5):305-313. doi: 10.1358/dot.2019.55.5.2969817.","Ielasi L","Drugs Today (Barc)","2019","2019/05/28","","","10.1358/dot.2019.55.5.2969817"
"31053989","Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)","Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y.","Med Oncol. 2019 May 3;36(6):52. doi: 10.1007/s12032-019-1272-2.","Hidaka H","Med Oncol","2019","2019/05/05","","","10.1007/s12032-019-1272-2"
"31171886","Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma","Choi C, Yoo GS, Cho WK, Park HC.","World J Gastroenterol. 2019 May 28;25(20):2416-2429. doi: 10.3748/wjg.v25.i20.2416.","Choi C","World J Gastroenterol","2019","2019/06/08","PMC6543238","","10.3748/wjg.v25.i20.2416"
"31171895","Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma","Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD.","World J Gastroenterol. 2019 May 28;25(20):2524-2538. doi: 10.3748/wjg.v25.i20.2524.","Barone M","World J Gastroenterol","2019","2019/06/08","PMC6543242","","10.3748/wjg.v25.i20.2524"
"31142283","The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis","Zhang Z, Zhou Y, Yang J, Hu K, Huang Y.","BMC Cancer. 2019 May 29;19(1):511. doi: 10.1186/s12885-019-5735-9.","Zhang Z","BMC Cancer","2019","2019/05/31","PMC6542001","","10.1186/s12885-019-5735-9"
"30788569","Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan","Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S.","J Gastroenterol. 2019 Jun;54(6):558-570. doi: 10.1007/s00535-019-01554-0. Epub 2019 Feb 20.","Kobayashi M","J Gastroenterol","2019","2019/02/22","PMC6536477","","10.1007/s00535-019-01554-0"
"30943423","Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival","Llovet JM, Montal R, Villanueva A.","J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31.","Llovet JM","J Hepatol","2019","2019/04/04","","","10.1016/j.jhep.2019.01.028"
"30943424","Trial endpoints for systemic therapy in patients with hepatocellular carcinoma","Meyer T, Johnson P.","J Hepatol. 2019 Jun;70(6):1060-1061. doi: 10.1016/j.jhep.2019.03.001. Epub 2019 Mar 31.","Meyer T","J Hepatol","2019","2019/04/04","","","10.1016/j.jhep.2019.03.001"
"30943425","Progression-free survival: Starting point or endpoint in advanced HCC trial design?","Finn RS.","J Hepatol. 2019 Jun;70(6):1062-1064. doi: 10.1016/j.jhep.2019.03.002. Epub 2019 Mar 31.","Finn RS","J Hepatol","2019","2019/04/04","","","10.1016/j.jhep.2019.03.002"
"31200350","Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma","Gyawali B.","J Natl Compr Canc Netw. 2019 Jun 1;17(6):760-762. doi: 10.6004/jnccn.2019.7317.","Gyawali B","J Natl Compr Canc Netw","2019","2019/06/15","","","10.6004/jnccn.2019.7317"
"31200357","Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma","Soto-Perez-de-Celis E, Aguiar PN, Cordón ML, Chavarri-Guerra Y, Lopes GL.","J Natl Compr Canc Netw. 2019 Jun 1;17(6):669-675. doi: 10.6004/jnccn.2018.7275.","Soto-Perez-de-Celis E","J Natl Compr Canc Netw","2019","2019/06/15","","","10.6004/jnccn.2018.7275"
"31167419","FGF19-FGFR4 Signaling in Hepatocellular Carcinoma","Raja A, Park I, Haq F, Ahn SM.","Cells. 2019 Jun 4;8(6):536. doi: 10.3390/cells8060536.","Raja A","Cells","2019","2019/06/07","PMC6627123","","10.3390/cells8060536"
"31216824","[Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma]","Lai JM, Hu S, Lin H, Luo H, Luo YB.","Zhonghua Zhong Liu Za Zhi. 2019 Jun 23;41(6):406-409. doi: 10.3760/cma.j.issn.0253-3766.2019.06.002.","Lai JM","Zhonghua Zhong Liu Za Zhi","2019","2019/06/21","","","10.3760/cma.j.issn.0253-3766.2019.06.002"
"31293335","Immunotherapy for hepatocellular carcinoma: Current and future","Johnston MP, Khakoo SI.","World J Gastroenterol. 2019 Jun 28;25(24):2977-2989. doi: 10.3748/wjg.v25.i24.2977.","Johnston MP","World J Gastroenterol","2019","2019/07/12","PMC6603808","","10.3748/wjg.v25.i24.2977"
"30896451","Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma","Delhaye C, Hendlisz A, Vouche M.","Curr Opin Oncol. 2019 Jul;31(4):339-345. doi: 10.1097/CCO.0000000000000539.","Delhaye C","Curr Opin Oncol","2019","2019/03/22","","","10.1097/CCO.0000000000000539"
"30954398","(125)I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis","Yuan D, Gao Z, Zhao J, Zhang H, Wang J.","Brachytherapy. 2019 Jul-Aug;18(4):521-529. doi: 10.1016/j.brachy.2019.01.014. Epub 2019 Apr 3.","Yuan D","Brachytherapy","2019","2019/04/08","","","10.1016/j.brachy.2019.01.014"
"31087772","The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation","Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Onali S, Hoppe-Lotichius M, Manzia TM, Nicolini D, Avolio AW, Mrzljak A, Kocman B, Agnes S, Vivarelli M, Tisone G, Otto G, Tsochatzis E, Rossi M, Viveiros A, Ciccarelli O, Cillo U, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group.","Liver Transpl. 2019 Jul;25(7):1023-1033. doi: 10.1002/lt.25492.","Lai Q","Liver Transpl","2019","2019/05/16","","","10.1002/lt.25492"
"31132887","Considerations of heterogeneity in clinical trials for hepatocellular carcinoma","Liu TH, Shao YY, Lu LC, Shen YC, Hsu C, Lin ZZ, Hsu CH, Cheng AL.","Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):615-621. doi: 10.1080/17474124.2019.1621165. Epub 2019 May 27.","Liu TH","Expert Rev Gastroenterol Hepatol","2019","2019/05/29","","","10.1080/17474124.2019.1621165"
"31204849","Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib","Personeni N, Pressiani T, Rimassa L.","Future Oncol. 2019 Jul;15(21):2449-2462. doi: 10.2217/fon-2019-0026. Epub 2019 Jun 17.","Personeni N","Future Oncol","2019","2019/06/18","","","10.2217/fon-2019-0026"
"31399171","Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis","Meyerovich G, Goykhman Y, Nakache R, Nachmany I, Lahat G, Shibolet O, Menachem Y, Katchman H, Wolf I, Geva R, Klausner JM, Lubezky N.","Transplant Proc. 2019 Jul-Aug;51(6):1867-1873. doi: 10.1016/j.transproceed.2019.02.030.","Meyerovich G","Transplant Proc","2019","2019/08/11","","","10.1016/j.transproceed.2019.02.030"
"31333308","Hepatocellular carcinoma: Mechanisms of progression and immunotherapy","Jiang Y, Han QJ, Zhang J.","World J Gastroenterol. 2019 Jul 7;25(25):3151-3167. doi: 10.3748/wjg.v25.i25.3151.","Jiang Y","World J Gastroenterol","2019","2019/07/24","PMC6626719","","10.3748/wjg.v25.i25.3151"
"31367163","Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis","Cao J, Kong FH, Liu X, Wang XB.","World J Gastroenterol. 2019 Jul 21;25(27):3649-3663. doi: 10.3748/wjg.v25.i27.3649.","Cao J","World J Gastroenterol","2019","2019/08/02","PMC6658393","","10.3748/wjg.v25.i27.3649"
"30939505","Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer","Huang Y, Cheng X, Sun P, Li T, Song Z, Zheng Q.","J Clin Gastroenterol. 2019 Aug;53(7):486-494. doi: 10.1097/MCG.0000000000001175.","Huang Y","J Clin Gastroenterol","2019","2019/04/03","","","10.1097/MCG.0000000000001175"
"31207163","Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma","He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M.","Cancer Med. 2019 Aug;8(9):4200-4213. doi: 10.1002/cam4.2355. Epub 2019 Jun 17.","He M","Cancer Med","2019","2019/06/18","PMC6675716","","10.1002/cam4.2355"
"31208929","Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019","Tovoli F, Casadei-Gardini A, Benevento F, Piscaglia F.","Dig Liver Dis. 2019 Aug;51(8):1067-1073. doi: 10.1016/j.dld.2019.05.006. Epub 2019 Jun 14.","Tovoli F","Dig Liver Dis","2019","2019/06/19","","","10.1016/j.dld.2019.05.006"
"31253577","Hepatocellular carcinoma: Current situation and challenge","Li Z, Zhu JY.","Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):303-304. doi: 10.1016/j.hbpd.2019.05.013. Epub 2019 Jun 11.","Li Z","Hepatobiliary Pancreat Dis Int","2019","2019/06/30","","","10.1016/j.hbpd.2019.05.013"
"31285588","Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials","Montal R, Andreu-Oller C, Bassaganyas L, Esteban-Fabró R, Moran S, Montironi C, Moeini A, Pinyol R, Peix J, Cabellos L, Villanueva A, Sia D, Mazzaferro V, Esteller M, Llovet JM.","Br J Cancer. 2019 Aug;121(4):340-343. doi: 10.1038/s41416-019-0513-7. Epub 2019 Jul 9.","Montal R","Br J Cancer","2019","2019/07/10","PMC6738090","","10.1038/s41416-019-0513-7"
"31435173","Multiple ""Omics"" data-based biomarker screening for hepatocellular carcinoma diagnosis","Liu XN, Cui DN, Li YF, Liu YH, Liu G, Liu L.","World J Gastroenterol. 2019 Aug 14;25(30):4199-4212. doi: 10.3748/wjg.v25.i30.4199.","Liu XN","World J Gastroenterol","2019","2019/08/23","PMC6700689","","10.3748/wjg.v25.i30.4199"
"31314948","Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications","Cariani E, Missale G.","Liver Int. 2019 Sep;39(9):1608-1621. doi: 10.1111/liv.14192. Epub 2019 Jul 28.","Cariani E","Liver Int","2019","2019/07/18","","","10.1111/liv.14192"
"31481419","Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma","Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM.","Cancer Res. 2019 Sep 1;79(17):4326-4330. doi: 10.1158/0008-5472.CAN-19-0803.","Yarchoan M","Cancer Res","2019","2019/09/05","PMC8330805","NIHMS1716346","10.1158/0008-5472.CAN-19-0803"
"31500650","From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma","Fu Y, Liu S, Zeng S, Shen H.","J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. doi: 10.1186/s13046-019-1396-4.","Fu Y","J Exp Clin Cancer Res","2019","2019/09/11","PMC6734524","","10.1186/s13046-019-1396-4"
"31569719","Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature","Reynaert H, Colle I.","Int J Mol Sci. 2019 Sep 27;20(19):4811. doi: 10.3390/ijms20194811.","Reynaert H","Int J Mol Sci","2019","2019/10/02","PMC6801667","","10.3390/ijms20194811"
"30833187","Impact of narrow margin and R1 resection for hepatocellular carcinoma on the salvage liver transplantation strategy. An intention-to-treat analysis","Lim C, Salloum C, Lahat E, Sotirov D, Eshkenazy R, Shwaartz C, Azoulay D.","HPB (Oxford). 2019 Oct;21(10):1295-1302. doi: 10.1016/j.hpb.2019.02.001. Epub 2019 Mar 1.","Lim C","HPB (Oxford)","2019","2019/03/06","","","10.1016/j.hpb.2019.02.001"
"31290997","Immune checkpoint inhibitors for hepatocellular carcinoma","El Dika I, Khalil DN, Abou-Alfa GK.","Cancer. 2019 Oct 1;125(19):3312-3319. doi: 10.1002/cncr.32076. Epub 2019 Jul 10.","El Dika I","Cancer","2019","2019/07/11","PMC7944520","NIHMS1635586","10.1002/cncr.32076"
"31371809","Insights into the success and failure of systemic therapy for hepatocellular carcinoma","Bruix J, da Fonseca LG, Reig M.","Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. doi: 10.1038/s41575-019-0179-x. Epub 2019 Aug 1.","Bruix J","Nat Rev Gastroenterol Hepatol","2019","2019/08/03","","","10.1038/s41575-019-0179-x"
"31378985","Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects","Lombardi A, Mondelli MU.","Aliment Pharmacol Ther. 2019 Oct;50(8):872-884. doi: 10.1111/apt.15449. Epub 2019 Aug 4.","Lombardi A","Aliment Pharmacol Ther","2019","2019/08/06","","","10.1111/apt.15449"
"31472742","The Unique Role of Fluorodeoxyglucose-PET in Radioembolization","Bastiaannet R, Lodge MA, de Jong HWAM, Lam MGEH.","PET Clin. 2019 Oct;14(4):447-457. doi: 10.1016/j.cpet.2019.06.002. Epub 2019 Jul 31.","Bastiaannet R","PET Clin","2019","2019/09/02","","","10.1016/j.cpet.2019.06.002"
"31577775","Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials","Chen QF, Wu PH, Huang T, Shen LJ, Huang ZL, Li W.","Medicine (Baltimore). 2019 Oct;98(40):e17460. doi: 10.1097/MD.0000000000017460.","Chen QF","Medicine (Baltimore)","2019","2019/10/03","PMC6783195","","10.1097/MD.0000000000017460"
"31588789","Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials","Cabibbo G, Cucchetti A, Cammà C, Casadei-Gardini A, Celsa C, Emanuele Maria Rizzo G, Johnson P, Ercolani G.","Future Oncol. 2019 Oct;15(29):3411-3422. doi: 10.2217/fon-2019-0287. Epub 2019 Oct 7.","Cabibbo G","Future Oncol","2019","2019/10/08","","","10.2217/fon-2019-0287"
"31603008","Cabozantinib for the treatment of hepatocellular carcinoma","Personeni N, Rimassa L, Pressiani T, Smiroldo V, Santoro A.","Expert Rev Anticancer Ther. 2019 Oct;19(10):847-855. doi: 10.1080/14737140.2019.1674141. Epub 2019 Oct 11.","Personeni N","Expert Rev Anticancer Ther","2019","2019/10/12","","","10.1080/14737140.2019.1674141"
"31599521","[Recent advances in managing hepatitis D]","Bonnemain CL, Cochand L, Portmann A, Béguelin C.","Rev Med Suisse. 2019 Oct 9;15(666):1802-1806.","Bonnemain CL","Rev Med Suisse","2019","2019/10/11","","",""
"31627733","Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response","Keenan BP, Fong L, Kelley RK.","J Immunother Cancer. 2019 Oct 18;7(1):267. doi: 10.1186/s40425-019-0749-z.","Keenan BP","J Immunother Cancer","2019","2019/10/20","PMC6798343","","10.1186/s40425-019-0749-z"
"31799685","Minimal impact of lenvatinib (Lenvima®) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. Two cases from the REFLECT study","Rinninella E, Cintoni M, Raoul P, Mele MC, De Gaetano AM, Marini MG, Mora V, Gasbarrini A.","Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):10132-10138. doi: 10.26355/eurrev_201911_19583.","Rinninella E","Eur Rev Med Pharmacol Sci","2019","2019/12/05","","","10.26355/eurrev_201911_19583"
"31799686","Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC)","Berretta M, Cobellis G, Franco R, Panarese I, Rinaldi B, Nasti G, Di Francia R, Rinaldi L.","Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):10139-10150. doi: 10.26355/eurrev_201911_19584.","Berretta M","Eur Rev Med Pharmacol Sci","2019","2019/12/05","","","10.26355/eurrev_201911_19584"
"31684985","Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma","Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J.","J Exp Clin Cancer Res. 2019 Nov 4;38(1):447. doi: 10.1186/s13046-019-1412-8.","Liu Z","J Exp Clin Cancer Res","2019","2019/11/06","PMC6827249","","10.1186/s13046-019-1412-8"
"30980680","Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma","Iida N, Mizukoshi E, Yamashita T, Terashima T, Arai K, Seishima J, Kaneko S.","Int J Cancer. 2019 Nov 15;145(10):2701-2711. doi: 10.1002/ijc.32339. Epub 2019 May 10.","Iida N","Int J Cancer","2019","2019/04/14","PMC6766885","","10.1002/ijc.32339"
"31751366","Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis","Chen MB, Wang H, Zheng QH, Zheng XW, Fan JN, Ding YL, Niu JL.","PLoS One. 2019 Nov 21;14(11):e0224773. doi: 10.1371/journal.pone.0224773. eCollection 2019.","Chen MB","PLoS One","2019","2019/11/22","PMC6872143","","10.1371/journal.pone.0224773"
"31783782","Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions","Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B.","J Immunother Cancer. 2019 Nov 29;7(1):333. doi: 10.1186/s40425-019-0824-5.","Hilmi M","J Immunother Cancer","2019","2019/12/01","PMC6884868","","10.1186/s40425-019-0824-5"
"31409568","Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin","Celik H, Wakim P, Pritchard WF, Castro M, Leonard S, Karanian JW, Dewhirst MW, Lencioni R, Wood BJ.","J Vasc Interv Radiol. 2019 Dec;30(12):1908-1914. doi: 10.1016/j.jvir.2019.04.023. Epub 2019 Aug 10.","Celik H","J Vasc Interv Radiol","2019","2019/08/15","PMC6875689","NIHMS1528191","10.1016/j.jvir.2019.04.023"
"31888534","Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","Gu Y, Yang X, Liang H, Li D.","BMC Gastroenterol. 2019 Dec 30;19(1):231. doi: 10.1186/s12876-019-1147-1.","Gu Y","BMC Gastroenterol","2019","2020/01/01","PMC6938024","","10.1186/s12876-019-1147-1"
"31449859","The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications","Hou J, Zhang H, Sun B, Karin M.","J Hepatol. 2020 Jan;72(1):167-182. doi: 10.1016/j.jhep.2019.08.014. Epub 2019 Aug 23.","Hou J","J Hepatol","2020","2019/08/27","","","10.1016/j.jhep.2019.08.014"
"31720835","REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H.","J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12.","Yamashita T","J Gastroenterol","2020","2019/11/14","PMC6942573","","10.1007/s00535-019-01642-1"
"31747082","Review article: new therapeutic interventions for advanced hepatocellular carcinoma","Bangaru S, Marrero JA, Singal AG.","Aliment Pharmacol Ther. 2020 Jan;51(1):78-89. doi: 10.1111/apt.15573. Epub 2019 Nov 20.","Bangaru S","Aliment Pharmacol Ther","2020","2019/11/21","","","10.1111/apt.15573"
"31830641","Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","Vogel A, Saborowski A.","Cancer Treat Rev. 2020 Jan;82:101946. doi: 10.1016/j.ctrv.2019.101946. Epub 2019 Nov 29.","Vogel A","Cancer Treat Rev","2020","2019/12/13","","","10.1016/j.ctrv.2019.101946"
"32474508","A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials","Wang H, Cao C, Wei X, Shen K, Shu Y, Wan X, Sun J, Ren X, Dong Y, Liu Y, Zhai B.","J Cancer Res Ther. 2020;16(2):243-249. doi: 10.4103/jcrt.JCRT_504_19.","Wang H","J Cancer Res Ther","2020","2020/06/01","","","10.4103/jcrt.JCRT_504_19"
"32865910","Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma","Sridhar S, Sharma I, Sankpal UT, Ghabach B, Narra K, Neerukonda L, Basha R.","Crit Rev Oncog. 2020;25(1):47-55. doi: 10.1615/CritRevOncog.2020034985.","Sridhar S","Crit Rev Oncog","2020","2020/09/01","PMC11079775","NIHMS1984895","10.1615/CritRevOncog.2020034985"
"31978267","Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma","Abdel-Rahman O, Elsayed Z.","Cochrane Database Syst Rev. 2020 Jan 24;1(1):CD011313. doi: 10.1002/14651858.CD011313.pub3.","Abdel-Rahman O","Cochrane Database Syst Rev","2020","2020/01/25","PMC6984619","","10.1002/14651858.CD011313.pub3"
"31780050","Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis","Terasawa M, Allard MA, Golse N, Sa Cunha A, Cherqui D, Adam R, Saiura A, Vibert E.","Surgery. 2020 Feb;167(2):425-431. doi: 10.1016/j.surg.2019.09.023. Epub 2019 Nov 25.","Terasawa M","Surgery","2020","2019/11/30","","","10.1016/j.surg.2019.09.023"
"31811905","Immunotherapy for hepatocellular carcinoma","Zongyi Y, Xiaowu L.","Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.","Zongyi Y","Cancer Lett","2020","2019/12/08","","","10.1016/j.canlet.2019.12.002"
"32645197","Patient Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard of Care Treatments","Wright KM.","Oncology (Williston Park). 2020 Feb 20;34(2):61-62.","Wright KM","Oncology (Williston Park)","2020","2020/07/10","","",""
"32521927","Clinical significance of changes in AFP, HTATIP2/TIP30, B7-H4 and inflammatory cytokines after transcatheter arterial chemoembolization","Zhang P, Chen Z, Chen L, Zang H, Zhu B, Shao W, Niu W.","J BUON. 2020 Mar-Apr;25(2):1206-1211.","Zhang P","J BUON","2020","2020/06/12","","",""
"32134981","First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials","Ding W, Tan Y, Qian Y, Xue W, Wang Y, Jiang P, Xu X.","PLoS One. 2020 Mar 5;15(3):e0229492. doi: 10.1371/journal.pone.0229492. eCollection 2020.","Ding W","PLoS One","2020","2020/03/06","PMC7058293","","10.1371/journal.pone.0229492"
"32294682","BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA","Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma; Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA.","Arq Gastroenterol. 2020 Mar 9;57(suppl 1):1-20. doi: 10.1590/S0004-2803.202000000-20. eCollection 2020.","Chagas AL","Arq Gastroenterol","2020","2020/04/16","","","10.1590/S0004-2803.202000000-20"
"32160231","Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review","Lin N, Li J, Ke Q, Xin F, Zeng Y, Wang L, Liu J.","PLoS One. 2020 Mar 11;15(3):e0229870. doi: 10.1371/journal.pone.0229870. eCollection 2020.","Lin N","PLoS One","2020","2020/03/12","PMC7065790","","10.1371/journal.pone.0229870"
"31158948","Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis","Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z.","Gut Liver. 2020 Mar 15;14(2):232-247. doi: 10.5009/gnl18546.","Wang X","Gut Liver","2020","2019/06/04","PMC7096226","","10.5009/gnl18546"
"31875523","Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches","Tagliamonte M, Mauriello A, Cavalluzzo B, Ragone C, Manolio C, Petrizzo A, Buonaguro L.","Cancer Lett. 2020 Mar 31;473:25-32. doi: 10.1016/j.canlet.2019.12.029. Epub 2019 Dec 23.","Tagliamonte M","Cancer Lett","2020","2019/12/26","","","10.1016/j.canlet.2019.12.029"
"32087191","Adoptive T-cell therapy for HBV-associated HCC and HBV infection","Tan AT, Schreiber S.","Antiviral Res. 2020 Apr;176:104748. doi: 10.1016/j.antiviral.2020.104748. Epub 2020 Feb 19.","Tan AT","Antiviral Res","2020","2020/02/23","","","10.1016/j.antiviral.2020.104748"
"32112736","Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere","Raoul JL, Edeline J.","Lancet Oncol. 2020 Apr;21(4):479-481. doi: 10.1016/S1470-2045(20)30082-6. Epub 2020 Feb 26.","Raoul JL","Lancet Oncol","2020","2020/03/01","","","10.1016/S1470-2045(20)30082-6"
"32390700","Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors","Piñero F, Silva M, Iavarone M.","World J Gastroenterol. 2020 Apr 28;26(16):1888-1900. doi: 10.3748/wjg.v26.i16.1888.","Piñero F","World J Gastroenterol","2020","2020/05/12","PMC7201145","","10.3748/wjg.v26.i16.1888"
"32162652","Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis","Li X, Liu L, Hu Y.","Biosci Rep. 2020 Apr 30;40(4):BSR20200232. doi: 10.1042/BSR20200232.","Li X","Biosci Rep","2020","2020/03/13","PMC7133516","","10.1042/BSR20200232"
"32101985","New systemic agents for hepatocellular carcinoma: an update 2020","von Felden J.","Curr Opin Gastroenterol. 2020 May;36(3):177-183. doi: 10.1097/MOG.0000000000000626.","von Felden J","Curr Opin Gastroenterol","2020","2020/02/27","","","10.1097/MOG.0000000000000626"
"32217150","Reasons to consider early treatment in chronic hepatitis B patients","Koffas A, Petersen J, Kennedy PT.","Antiviral Res. 2020 May;177:104783. doi: 10.1016/j.antiviral.2020.104783. Epub 2020 Mar 23.","Koffas A","Antiviral Res","2020","2020/03/29","","","10.1016/j.antiviral.2020.104783"
"32352320","IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation","Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S.","Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30.","Hack SP","Future Oncol","2020","2020/05/01","","","10.2217/fon-2020-0162"
"32536773","Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations","da Costa AC, Sodergren M, Jayant K, Santa Cruz F, Spalding D, Pai M, Habib N.","World J Gastroenterol. 2020 May 7;26(17):2040-2048. doi: 10.3748/wjg.v26.i17.2040.","da Costa AC","World J Gastroenterol","2020","2020/06/16","PMC7267689","","10.3748/wjg.v26.i17.2040"
"32402160","Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators.","N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.","Finn RS","N Engl J Med","2020","2020/05/14","","","10.1056/NEJMoa1915745"
"32547550","Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review","Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Jiang W, Fang W.","Front Immunol. 2020 May 28;11:1037. doi: 10.3389/fimmu.2020.01037. eCollection 2020.","Li B","Front Immunol","2020","2020/06/18","PMC7270402","","10.3389/fimmu.2020.01037"
"31734238","Comparative analysis of outcomes after liver resection and liver transplantation for early stages hepatocellular carcinoma in HIV-infected patients. An intention-to-treat analysis","Golse N, Duarte P, Fontana A, Bündchen C, Karam V, Allard MA, Pittau G, Ciacio O, Duclos-Vallée JC, Sa Cunha A, Castaing D, Cherqui D, Adam R, Samuel D, Vibert E.","HPB (Oxford). 2020 Jun;22(6):900-910. doi: 10.1016/j.hpb.2019.10.014. Epub 2019 Nov 14.","Golse N","HPB (Oxford)","2020","2019/11/18","","","10.1016/j.hpb.2019.10.014"
"31863306","Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check","Lee A, Lee FC.","Front Med. 2020 Jun;14(3):273-283. doi: 10.1007/s11684-019-0728-2. Epub 2019 Dec 21.","Lee A","Front Med","2020","2019/12/22","","","10.1007/s11684-019-0728-2"
"32095855","Impact on Oncological Outcomes and Intent-to-Treat Survival of Resection Margin for Transplantable Hepatocellular Carcinoma in All-Comers and in Patients with Cirrhosis: A Multicenter Study","Lim C, Goumard C, Casellas-Robert M, Lopez-Ben S, Lladó L, Busquets J, Salloum C, Albiol-Quer MT, Castro-Gutiérrez E, Rosmorduc O, Feray C, Ramos E, Figueras J, Scatton O, Azoulay D.","World J Surg. 2020 Jun;44(6):1966-1974. doi: 10.1007/s00268-020-05424-2.","Lim C","World J Surg","2020","2020/02/26","","","10.1007/s00268-020-05424-2"
"32402299","Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma","Mejia JC, Pasko J.","Surg Clin North Am. 2020 Jun;100(3):535-549. doi: 10.1016/j.suc.2020.02.013. Epub 2020 Apr 16.","Mejia JC","Surg Clin North Am","2020","2020/05/14","","","10.1016/j.suc.2020.02.013"
"32424805","Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma","Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK.","Adv Ther. 2020 Jun;37(6):2678-2695. doi: 10.1007/s12325-020-01378-y. Epub 2020 May 18.","Kelley RK","Adv Ther","2020","2020/05/20","PMC7467441","","10.1007/s12325-020-01378-y"
"32340652","Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment","Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A.","Gene Expr. 2020 Jun 12;20(1):53-65. doi: 10.3727/105221620X15880179864121. Epub 2020 Apr 27.","Onuma AE","Gene Expr","2020","2020/04/29","PMC7284108","","10.3727/105221620X15880179864121"
"32575734","Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma","Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z.","Int J Mol Sci. 2020 Jun 20;21(12):4398. doi: 10.3390/ijms21124398.","Dumolard L","Int J Mol Sci","2020","2020/06/25","PMC7352237","","10.3390/ijms21124398"
"32246741","The Role of Salvage Transplantation in Patients Initially Treated With Open Versus Minimally Invasive Liver Surgery: An Intention-to-Treat Analysis","Levi Sandri GB, Lai Q, Ravaioli M, Di Sandro S, Balzano E, Pagano D, Magistri P, Di Benedetto F, Rossi M, Gruttadauria S, De Simone P, Ettorre GM, De Carlis L, Cescon M, Colasanti M, Mennini G, Serenari M, Ferla F, Tincani G, Francesco FD, Guidetti C.","Liver Transpl. 2020 Jul;26(7):878-887. doi: 10.1002/lt.25768. Epub 2020 Jun 25.","Levi Sandri GB","Liver Transpl","2020","2020/04/05","","","10.1002/lt.25768"
"32249635","Nivolumab for the treatment of hepatocellular carcinoma","Chiew Woon L, Joycelyn Jie Xin L, Su Pin C.","Expert Opin Biol Ther. 2020 Jul;20(7):687-693. doi: 10.1080/14712598.2020.1749593. Epub 2020 Apr 20.","Chiew Woon L","Expert Opin Biol Ther","2020","2020/04/07","","","10.1080/14712598.2020.1749593"
"32378799","Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab","Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R.","Cancer Med. 2020 Jul;9(13):4640-4647. doi: 10.1002/cam4.3116. Epub 2020 May 7.","Fung AS","Cancer Med","2020","2020/05/08","PMC7333842","","10.1002/cam4.3116"
"32491932","Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design","Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L.","Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3.","Kelley RK","Future Oncol","2020","2020/06/04","","","10.2217/fon-2020-0283"
"32664640","The Use of Stem Cell Differentiation Stage Factors (SCDSFs) Taken from Zebrafish Embryos during Organogenesis and Their Role in Regulating the Gene Expression of Normal and Pathological (Stem) Cells","Biava PM.","Int J Mol Sci. 2020 Jul 12;21(14):4914. doi: 10.3390/ijms21144914.","Biava PM","Int J Mol Sci","2020","2020/07/16","PMC7404112","","10.3390/ijms21144914"
"31959487","Resection or radiofrequency ablation for hepatocellular carcinoma? Assessment of validity of current studies, meta-analyses and their influence on guidelines","Manzini G, Hines IN, Henne-Bruns D, Kremer M.","HPB (Oxford). 2020 Aug;22(8):1206-1215. doi: 10.1016/j.hpb.2019.12.009. Epub 2020 Jan 18.","Manzini G","HPB (Oxford)","2020","2020/01/22","","","10.1016/j.hpb.2019.12.009"
"32371538","Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials","Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, Yuan D, Ma H, Wang H, Li Z, Zhai B.","Clin Cancer Res. 2020 Aug 1;26(15):3979-3989. doi: 10.1158/1078-0432.CCR-19-3259. Epub 2020 May 5.","Shi D","Clin Cancer Res","2020","2020/05/07","","","10.1158/1078-0432.CCR-19-3259"
"32413500","Anatomic versus non-anatomic resection for hepatocellular carcinoma, do we have an answer? A meta-analysis","Jiao S, Li G, Zhang D, Xu Y, Liu J, Li G.","Int J Surg. 2020 Aug;80:243-255. doi: 10.1016/j.ijsu.2020.05.008. Epub 2020 May 13.","Jiao S","Int J Surg","2020","2020/05/16","","","10.1016/j.ijsu.2020.05.008"
"32522600","New insights on sorafenib resistance in liver cancer with correlation of individualized therapy","Cheng Z, Wei-Qi J, Jin D.","Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188382. doi: 10.1016/j.bbcan.2020.188382. Epub 2020 Jun 6.","Cheng Z","Biochim Biophys Acta Rev Cancer","2020","2020/06/12","","","10.1016/j.bbcan.2020.188382"
"32671491","[Immuno-oncology : No longer a need for interventional radiology?]","Saborowski A, Vogel A.","Radiologe. 2020 Aug;60(8):687-692. doi: 10.1007/s00117-020-00722-1.","Saborowski A","Radiologe","2020","2020/07/17","","","10.1007/s00117-020-00722-1"
"32671719","Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives","Trojan J.","Drugs. 2020 Aug;80(12):1203-1210. doi: 10.1007/s40265-020-01361-5.","Trojan J","Drugs","2020","2020/07/17","PMC7395054","","10.1007/s40265-020-01361-5"
"32846865","Effect of sodium cantharidinate/vitamin B6 injection on survival, liver function, immune function, and quality of life in patients with hepatocellular carcinoma: Protocol for a meta-analysis","Zhu M, Liu X, Zhou C, Li J.","Medicine (Baltimore). 2020 Aug 21;99(34):e21952. doi: 10.1097/MD.0000000000021952.","Zhu M","Medicine (Baltimore)","2020","2020/08/28","PMC7447480","","10.1097/MD.0000000000021952"
"32602828","Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with (90)Y in the SARAH Study","Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group.","Radiology. 2020 Sep;296(3):673-684. doi: 10.1148/radiol.2020191606. Epub 2020 Jun 30.","Hermann AL","Radiology","2020","2020/07/01","","","10.1148/radiol.2020191606"
"32661949","Novel systemic therapy for hepatocellular carcinoma","Dong Y, Liu TH, Yau T, Hsu C.","Hepatol Int. 2020 Sep;14(5):638-651. doi: 10.1007/s12072-020-10073-7. Epub 2020 Jul 13.","Dong Y","Hepatol Int","2020","2020/07/15","","","10.1007/s12072-020-10073-7"
"32947972","NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling","Sunami Y.","Int J Mol Sci. 2020 Sep 16;21(18):6799. doi: 10.3390/ijms21186799.","Sunami Y","Int J Mol Sci","2020","2020/09/19","PMC7555727","","10.3390/ijms21186799"
"31959566","Evaluation of efficacy, safety and treatment-related outcomes of percutaneous radiofrequency ablation versus partial hepatectomy for small primary liver cancer meeting the Milan criteria: A systematic review and meta-analysis of randomized controlled trials","Yu C, Wu S, Zhao J, Lu J, Zhao T, Wei Y, Long C, Lin T, He D, Wei G.","Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):718-732. doi: 10.1016/j.clinre.2019.12.012. Epub 2020 Jan 17.","Yu C","Clin Res Hepatol Gastroenterol","2020","2020/01/22","","","10.1016/j.clinre.2019.12.012"
"32162677","Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era","Juengpanich S, Topatana W, Lu C, Staiculescu D, Li S, Cao J, Lin J, Hu J, Chen M, Chen J, Cai X.","Int J Cancer. 2020 Oct 1;147(7):1778-1792. doi: 10.1002/ijc.32970. Epub 2020 Apr 15.","Juengpanich S","Int J Cancer","2020","2020/03/13","","","10.1002/ijc.32970"
"32356156","Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported","Grégory J, Créquit P, Vilgrain V, Ronot M, Boutron I.","Eur Radiol. 2020 Oct;30(10):5633-5640. doi: 10.1007/s00330-020-06900-y. Epub 2020 Apr 30.","Grégory J","Eur Radiol","2020","2020/05/02","","","10.1007/s00330-020-06900-y"
"32449002","The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib","Ruanglertboon W, Sorich MJ, Logan JM, Rowland A, Hopkins AM.","J Cancer Res Clin Oncol. 2020 Oct;146(10):2693-2697. doi: 10.1007/s00432-020-03261-3. Epub 2020 May 24.","Ruanglertboon W","J Cancer Res Clin Oncol","2020","2020/05/26","","","10.1007/s00432-020-03261-3"
"32500344","Is Postoperative Adjuvant Transcatheter Arterial Infusion Therapy Effective for Patients with Hepatocellular Carcinoma who Underwent Hepatectomy? A Prospective Randomized Controlled Trial","Hirokawa F, Komeda K, Taniguchi K, Asakuma M, Shimizu T, Inoue Y, Kagota S, Tomioka A, Yamamoto K, Uchiyama K.","Ann Surg Oncol. 2020 Oct;27(11):4143-4152. doi: 10.1245/s10434-020-08699-w. Epub 2020 Jun 4.","Hirokawa F","Ann Surg Oncol","2020","2020/06/06","","","10.1245/s10434-020-08699-w"
"32529273","Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody","Labadie KP, Sham JG.","Ann Surg Oncol. 2020 Oct;27(11):4070-4072. doi: 10.1245/s10434-020-08702-4. Epub 2020 Jun 4.","Labadie KP","Ann Surg Oncol","2020","2020/06/13","","","10.1245/s10434-020-08702-4"
"32889778","Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival","Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y.","Cancer Sci. 2020 Nov;111(11):4218-4231. doi: 10.1111/cas.14641. Epub 2020 Sep 24.","Qin SK","Cancer Sci","2020","2020/09/05","PMC7648021","","10.1111/cas.14641"
"32889867","mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors","Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK.","Ann Surg. 2020 Nov;272(5):855-862. doi: 10.1097/SLA.0000000000004280.","Schnitzbauer AA","Ann Surg","2020","2020/09/05","","","10.1097/SLA.0000000000004280"
"33343209","Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions","Weinmann A, Galle PR.","Curr Oncol. 2020 Nov;27(Suppl 3):S152-S164. doi: 10.3747/co.27.7315. Epub 2020 Nov 1.","Weinmann A","Curr Oncol","2020","2020/12/21","PMC7739523","","10.3747/co.27.7315"
"33197051","Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma","Abdel-Rahman O, Elsayed Z.","Cochrane Database Syst Rev. 2020 Nov 16;11(11):CD011313. doi: 10.1002/14651858.CD011313.pub4.","Abdel-Rahman O","Cochrane Database Syst Rev","2020","2020/11/16","PMC8215872","","10.1002/14651858.CD011313.pub4"
"32767901","Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population","Jia S, Fu Y, Tao H.","Pharm Biol. 2020 Dec;58(1):771-784. doi: 10.1080/13880209.2020.1799040.","Jia S","Pharm Biol","2020","2020/08/10","PMC7470052","","10.1080/13880209.2020.1799040"
"33007432","Immunotherapy for advanced hepatocellular carcinoma, where are we?","Zhang L, Ding J, Li HY, Wang ZH, Wu J.","Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188441. doi: 10.1016/j.bbcan.2020.188441. Epub 2020 Sep 30.","Zhang L","Biochim Biophys Acta Rev Cancer","2020","2020/10/02","","","10.1016/j.bbcan.2020.188441"
"33090186","Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis","Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T.","JAMA Oncol. 2020 Dec 1;6(12):e204930. doi: 10.1001/jamaoncol.2020.4930. Epub 2020 Dec 10.","Sonbol MB","JAMA Oncol","2020","2020/10/22","PMC7582230","","10.1001/jamaoncol.2020.4930"
"33288552","Alternative Biomarkers to Predict Tumor Biology in Hepatocellular Carcinoma","Abreu P, Ferreira R, Mineli V, Ribeiro MA, Ferreira FG, DE Mello Vianna RM, Tomasich FDS, Szutan LA.","Anticancer Res. 2020 Dec;40(12):6573-6784. doi: 10.21873/anticanres.14682. Epub 2020 Dec 7.","Abreu P","Anticancer Res","2020","2020/12/08","","","10.21873/anticanres.14682"
"31898106","Is It Just a Matter of Surgical Extension to Achieve the Cure of Hepatocarcinoma? A Meta-Analysis of Propensity-Matched and Randomized Studies for Anatomic Versus Parenchyma-Sparing Liver Resection","Famularo S, Ceresoli M, Giani A, Ciulli C, Pinotti E, Romano F, Braga M, De Carlis L, Gianotti L.","J Gastrointest Surg. 2021 Jan;25(1):94-103. doi: 10.1007/s11605-019-04494-5. Epub 2020 Jan 2.","Famularo S","J Gastrointest Surg","2021","2020/01/04","","","10.1007/s11605-019-04494-5"
"32277491","Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis","Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, Singh S, Loomba R.","Hepatology. 2021 Jan;73(1):68-78. doi: 10.1002/hep.31267. Epub 2020 Nov 6.","Dave S","Hepatology","2021","2020/04/12","PMC8022893","NIHMS1681585","10.1002/hep.31267"
"32430997","Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference","Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC.","Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.","Llovet JM","Hepatology","2021","2020/05/21","","","10.1002/hep.31327"
"33429736","Efficacy and safety of radiofrequency ablation versus laparoscopic hepatectomy for small hepatocellular carcinoma: A protocol for a randomized controlled trial","Zhu F, Chang Q, Duan S, Leng W.","Medicine (Baltimore). 2021 Jan 8;100(1):e23678. doi: 10.1097/MD.0000000000023678.","Zhu F","Medicine (Baltimore)","2021","2021/01/12","PMC7793421","","10.1097/MD.0000000000023678"
"33211092","Systemic targeted and immunotherapy for advanced hepatocellular carcinoma","Cersosimo RJ.","Am J Health Syst Pharm. 2021 Jan 22;78(3):187-202. doi: 10.1093/ajhp/zxaa365.","Cersosimo RJ","Am J Health Syst Pharm","2021","2020/11/19","","","10.1093/ajhp/zxaa365"
"33504909","Comparison of deep and moderate neuromuscular blockade in microwave ablation of liver tumours: a randomized-controlled clinical trial","Loh PS, Yeong CH, Masohood NS, Sulaiman N, Zaki RA, Fabell K, Abdullah BJJ.","Sci Rep. 2021 Jan 27;11(1):2299. doi: 10.1038/s41598-021-81913-1.","Loh PS","Sci Rep","2021","2021/01/28","PMC7840903","","10.1038/s41598-021-81913-1"
"32767586","Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies","Lu L, Jiang J, Zhan M, Zhang H, Wang QT, Sun SN, Guo XK, Yin H, Wei Y, Li SY, Liu JO, Li Y, He YW.","Hepatology. 2021 Feb;73(2):821-832. doi: 10.1002/hep.31502.","Lu L","Hepatology","2021","2020/08/09","","","10.1002/hep.31502"
"32898239","Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review","Lim H, Ramjeesingh R, Liu D, Tam VC, Knox JJ, Card PB, Meyers BM.","J Natl Cancer Inst. 2021 Feb 1;113(2):123-136. doi: 10.1093/jnci/djaa119.","Lim H","J Natl Cancer Inst","2021","2020/09/08","PMC7850551","","10.1093/jnci/djaa119"
"33541088","Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma","Uson Junior PLS, Liu AJ, Sonbol MB, Borad MJ, Bekaii-Saab TS.","Chin Clin Oncol. 2021 Feb;10(1):11. doi: 10.21037/cco-20-231.","Uson Junior PLS","Chin Clin Oncol","2021","2021/02/05","","","10.21037/cco-20-231"
"33540837","From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis","Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C.","Int J Mol Sci. 2021 Feb 2;22(3):1492. doi: 10.3390/ijms22031492.","Mohr R","Int J Mol Sci","2021","2021/02/05","PMC7867354","","10.3390/ijms22031492"
"33563246","Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria","Sun X, Li L, Xu L, Zhou Z, Chen J, Wang J, Zhang Y, Hu D, Chen M.","BMC Cancer. 2021 Feb 9;21(1):147. doi: 10.1186/s12885-021-07870-0.","Sun X","BMC Cancer","2021","2021/02/10","PMC7871582","","10.1186/s12885-021-07870-0"
"33131346","A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials","Pollock RF, Brennan VK, Shergill S, Colaone F.","Expert Rev Anticancer Ther. 2021 Mar;21(3):341-349. doi: 10.1080/14737140.2021.1842204. Epub 2021 Feb 10.","Pollock RF","Expert Rev Anticancer Ther","2021","2020/11/02","","","10.1080/14737140.2021.1842204"
"33508960","Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy","Rizzo A, Ricci AD, Brandi G.","Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.","Rizzo A","Future Oncol","2021","2021/01/29","","","10.2217/fon-2020-0986"
"33790915","Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma","Sharma R, Motedayen Aval L.","Front Immunol. 2021 Mar 15;12:652007. doi: 10.3389/fimmu.2021.652007. eCollection 2021.","Sharma R","Front Immunol","2021","2021/04/01","PMC8005707","","10.3389/fimmu.2021.652007"
"33859646","Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma","Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C.","Front Immunol. 2021 Mar 30;12:652172. doi: 10.3389/fimmu.2021.652172. eCollection 2021.","Mohr R","Front Immunol","2021","2021/04/16","PMC8042255","","10.3389/fimmu.2021.652172"
"33309569","Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials","Kamarajah SK, Bundred JR, Littler P, Reeves H, Manas DM, White SA.","HPB (Oxford). 2021 Apr;23(4):495-505. doi: 10.1016/j.hpb.2020.10.031. Epub 2020 Dec 11.","Kamarajah SK","HPB (Oxford)","2021","2020/12/14","","","10.1016/j.hpb.2020.10.031"
"33836710","Frequent fragility of randomized controlled trials for HCC treatment","Zhang H, Li J, Zeng W.","BMC Cancer. 2021 Apr 9;21(1):389. doi: 10.1186/s12885-021-08133-8.","Zhang H","BMC Cancer","2021","2021/04/10","PMC8034173","","10.1186/s12885-021-08133-8"
"33510460","Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R.","Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293-313. doi: 10.1038/s41575-020-00395-0. Epub 2021 Jan 28.","Llovet JM","Nat Rev Gastroenterol Hepatol","2021","2021/01/29","","","10.1038/s41575-020-00395-0"
"34268950","Which is the best combination of surgery for hepatocellular carcinoma with hepatic/portal vein thrombosis in China: a network meta-analysis of randomized controlled trials","Wu QQ, Chen YX, Zheng TT, Dai MT, Ye T, Xu YH, Hu Y, Du SS, Zeng ZC.","J BUON. 2021 May-Jun;26(3):889-896.","Wu QQ","J BUON","2021","2021/07/16","","",""
"33941111","Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring","Lee YYD, Nguyen DT, Moodie T, O'Brien R, McMaster A, Hickey A, Pritchard N, Poulsen P, Tabaksblat EM, Weber B, Worm E, Pryor D, Chu J, Hardcastle N, Booth J, Gebski V, Wang T, Keall P.","BMC Cancer. 2021 May 3;21(1):494. doi: 10.1186/s12885-021-08184-x.","Lee YYD","BMC Cancer","2021","2021/05/04","PMC8091536","","10.1186/s12885-021-08184-x"
"34006331","Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets","Luo XY, Wu KM, He XX.","J Exp Clin Cancer Res. 2021 May 18;40(1):172. doi: 10.1186/s13046-021-01968-w.","Luo XY","J Exp Clin Cancer Res","2021","2021/05/19","PMC8130401","","10.1186/s13046-021-01968-w"
"34040331","Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials","Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF.","World J Gastroenterol. 2021 May 21;27(19):2415-2433. doi: 10.3748/wjg.v27.i19.2415.","Han Y","World J Gastroenterol","2021","2021/05/27","PMC8130040","","10.3748/wjg.v27.i19.2415"
"33434363","Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma","Kalasekar SM, Garrido-Laguna I, Evason KJ.","Hepatology. 2021 Jun;73(6):2591-2593. doi: 10.1002/hep.31706. Epub 2021 May 21.","Kalasekar SM","Hepatology","2021","2021/01/12","","","10.1002/hep.31706"
"33556420","Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot","Bruix J.","J Hepatol. 2021 Jun;74(6):1483-1488. doi: 10.1016/j.jhep.2021.01.033. Epub 2021 Feb 5.","Bruix J","J Hepatol","2021","2021/02/08","","","10.1016/j.jhep.2021.01.033"
"33666530","Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib","Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T.","Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):589-598. doi: 10.1080/17474124.2021.1899808. Epub 2021 Mar 19.","Tsang J","Expert Rev Gastroenterol Hepatol","2021","2021/03/05","","","10.1080/17474124.2021.1899808"
"34043158","Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial","Vogl TJ, Langenbach MC, Hammerstingl R, Albrecht MH, Chatterjee AR, Gruber-Rouh T.","Hepatol Int. 2021 Jun;15(3):685-694. doi: 10.1007/s12072-021-10193-8. Epub 2021 May 27.","Vogl TJ","Hepatol Int","2021","2021/05/27","PMC8286929","","10.1007/s12072-021-10193-8"
"34203895","Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma","Lim Y, Ku NO.","Int J Mol Sci. 2021 Jun 15;22(12):6401. doi: 10.3390/ijms22126401.","Lim Y","Int J Mol Sci","2021","2021/07/02","PMC8232640","","10.3390/ijms22126401"
"34167181","Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis","Spiliotis AE, Gäbelein G, Holländer S, Scherber PR, Glanemann M, Patel B.","Radiol Oncol. 2021 Jun 25;55(3):247-258. doi: 10.2478/raon-2021-0030.","Spiliotis AE","Radiol Oncol","2021","2021/06/24","PMC8366737","","10.2478/raon-2021-0030"
"33356655","Microwave ablation determines similar survival outcomes as compared to radiofrequency ablation for the treatment of hepatocellular carcinoma","Khan A, Mostowy M, Owusu M, Mutambanengwe M, Habimana S, Bence S, Facciorusso A.","Expert Rev Gastroenterol Hepatol. 2021 Jul;15(7):829-833. doi: 10.1080/17474124.2021.1869939. Epub 2020 Dec 30.","Khan A","Expert Rev Gastroenterol Hepatol","2021","2020/12/28","","","10.1080/17474124.2021.1869939"
"33369758","Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma","Pinato DJ, Fessas P, Sapisochin G, Marron TU.","Hepatology. 2021 Jul;74(1):483-490. doi: 10.1002/hep.31697. Epub 2021 Jun 28.","Pinato DJ","Hepatology","2021","2020/12/28","","","10.1002/hep.31697"
"33404115","Comparison of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: a meta-analysis","Wang Q, Tang M, Zhang S.","ANZ J Surg. 2021 Jul;91(7-8):E432-E438. doi: 10.1111/ans.16560. Epub 2021 Jan 6.","Wang Q","ANZ J Surg","2021","2021/01/06","","","10.1111/ans.16560"
"33569810","Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials","Jia Z, Zhang H, Li N.","J Gastroenterol Hepatol. 2021 Jul;36(7):1769-1777. doi: 10.1111/jgh.15440. Epub 2021 Feb 25.","Jia Z","J Gastroenterol Hepatol","2021","2021/02/11","","","10.1111/jgh.15440"
"33741847","Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials","Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, Nevens F, Suh KS, Fischer L, Jin Joo D, Fung J, Joh JW, Kaido T, Grant D, Meier M, Rauer B, Sips C, Kaneko S, Levy G.","Transplantation. 2021 Jul 1;105(7):1564-1575. doi: 10.1097/TP.0000000000003394.","Lee SG","Transplantation","2021","2021/03/20","PMC8221719","","10.1097/TP.0000000000003394"
"33867478","The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together","D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L.","Curr Opin Oncol. 2021 Jul 1;33(4):386-394. doi: 10.1097/CCO.0000000000000744.","D'Alessio A","Curr Opin Oncol","2021","2021/04/19","","","10.1097/CCO.0000000000000744"
"33966002","Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?","Hendlisz A, Sclafani F.","Curr Opin Oncol. 2021 Jul 1;33(4):351-352. doi: 10.1097/CCO.0000000000000749.","Hendlisz A","Curr Opin Oncol","2021","2021/05/09","","","10.1097/CCO.0000000000000749"
"33870454","Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials","Yu Q, Liu C, Navuluri R, Ahmed O.","Abdom Radiol (NY). 2021 Sep;46(9):4467-4475. doi: 10.1007/s00261-021-03080-1. Epub 2021 Apr 18.","Yu Q","Abdom Radiol (NY)","2021","2021/04/19","","","10.1007/s00261-021-03080-1"
"34126063","Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)","Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM.","Gastroenterology. 2021 Sep;161(3):879-898. doi: 10.1053/j.gastro.2021.06.008. Epub 2021 Jun 12.","Haber PK","Gastroenterology","2021","2021/06/14","","","10.1053/j.gastro.2021.06.008"
"34259797","Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant","Lai Q, Sapisochin G, Gorgen A, Vitale A, Halazun KJ, Iesari S, Schaefer B, Bhangui P, Mennini G, Wong TCL, Uemoto S, Lin CC, Mittler J, Ikegami T, Yang Z, Frigo AC, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut JP.","JAMA Surg. 2021 Sep 1;156(9):e213112. doi: 10.1001/jamasurg.2021.3112. Epub 2021 Sep 8.","Lai Q","JAMA Surg","2021","2021/07/14","PMC8281041","","10.1001/jamasurg.2021.3112"
"34570206","Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma","Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z.","JAMA Netw Open. 2021 Sep 1;4(9):e2126992. doi: 10.1001/jamanetworkopen.2021.26992.","Zhang YJ","JAMA Netw Open","2021","2021/09/27","PMC8477266","","10.1001/jamanetworkopen.2021.26992"
"34761604","Comparing the efficacy and safety of local-regional treatments for hepatocellular carcinoma with portal/hepatic vein tumor thrombosis in China: a network meta-analysis of randomized controlled trials","Wu QQ, Gao H, Du SS, Chen YX, Hu Y, Yang P, Hou JZ, Zeng ZC.","J BUON. 2021 Sep-Oct;26(5):1950-1957.","Wu QQ","J BUON","2021","2021/11/11","","",""
"34559096","Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis","Chen J, Wang J, Xie F.","Medicine (Baltimore). 2021 Sep 24;100(38):e27013. doi: 10.1097/MD.0000000000027013.","Chen J","Medicine (Baltimore)","2021","2021/09/24","PMC8462645","","10.1097/MD.0000000000027013"
"34425474","Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment","Zhu H, Wang SY, Zhu JH, Liu H, Kong M, Mao Q, Zhang W, Li SL.","Phytomedicine. 2021 Oct;91:153700. doi: 10.1016/j.phymed.2021.153700. Epub 2021 Aug 8.","Zhu H","Phytomedicine","2021","2021/08/23","","","10.1016/j.phymed.2021.153700"
"34649610","YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial","Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Yao ZA, Qiang R, Chen ST, Zhao X, Liu S, Cao ZM, Xu L, Li GH, Chen J, Wang L.","Trials. 2021 Oct 14;22(1):701. doi: 10.1186/s13063-021-05650-6.","Wu QJ","Trials","2021","2021/10/15","PMC8515328","","10.1186/s13063-021-05650-6"
"33463734","HCC Detection on Surveillance US: Comparing Focused Liver Protocol Using US LI-RADS Technical Guidelines to a General Complete Abdominal US Protocol","da Silva PH, Gomes MM, de Matos CAL, de Souza E Silva IS, Gonzalez AM, Torres US, Salazar GMM, D'Ippolito G.","J Ultrasound Med. 2021 Nov;40(11):2487-2495. doi: 10.1002/jum.15637. Epub 2021 Jan 19.","da Silva PH","J Ultrasound Med","2021","2021/01/19","","","10.1002/jum.15637"
"34173317","Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology","Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX.","Liver Int. 2021 Nov;41(11):2759-2767. doi: 10.1111/liv.14994. Epub 2021 Aug 8.","Galle PR","Liver Int","2021","2021/06/26","","","10.1111/liv.14994"
"34334642","Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy?: A Retrospective Multicentric Study","Chebaro A, Buc E, Durin T, Chiche L, Brustia R, Didier A, Pruvot FR, Kitano Y, Muscari F, Lecolle K, Sulpice L, Sonmez E, Bougard M, El Amrani M, Sommacale D, Maulat C, Ayav A, Adam R, Laurent C, Truant S.","Ann Surg. 2021 Nov 1;274(5):874-880. doi: 10.1097/SLA.0000000000005121.","Chebaro A","Ann Surg","2021","2021/08/02","","","10.1097/SLA.0000000000005121"
"34508996","Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice","Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L.","Eur J Cancer. 2021 Nov;157:140-152. doi: 10.1016/j.ejca.2021.08.020. Epub 2021 Sep 8.","Pinato DJ","Eur J Cancer","2021","2021/09/11","","","10.1016/j.ejca.2021.08.020"
"34537483","Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma","Liu T, Li Q, Lin Z, Wang P, Chen Y, Fu Y, Ding Z.","Int Immunopharmacol. 2021 Nov;100:108128. doi: 10.1016/j.intimp.2021.108128. Epub 2021 Sep 17.","Liu T","Int Immunopharmacol","2021","2021/09/19","","","10.1016/j.intimp.2021.108128"
"34872286","Exploring the effect of microecological agents on postoperative immune function in patients undergoing liver cancer surgery: a systematic review and meta-analysis","Xiang Y, Zhang S, Cui Z, Yang Y.","Ann Palliat Med. 2021 Nov;10(11):11615-11627. doi: 10.21037/apm-21-2669.","Xiang Y","Ann Palliat Med","2021","2021/12/07","","","10.21037/apm-21-2669"
"34804015","Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?","Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K.","Front Immunol. 2021 Nov 2;12:731527. doi: 10.3389/fimmu.2021.731527. eCollection 2021.","Zhao S","Front Immunol","2021","2021/11/22","PMC8600564","","10.3389/fimmu.2021.731527"
"34899747","Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma","Xing R, Gao J, Cui Q, Wang Q.","Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.","Xing R","Front Immunol","2021","2021/12/13","PMC8660685","","10.3389/fimmu.2021.783236"
"34884684","Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma","Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ.","Int J Mol Sci. 2021 Nov 28;22(23):12880. doi: 10.3390/ijms222312880.","Chen CT","Int J Mol Sci","2021","2021/12/10","PMC8657421","","10.3390/ijms222312880"
"33745079","Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis","Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A.","J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20.","Casadei-Gardini A","J Cancer Res Clin Oncol","2021","2021/03/21","","","10.1007/s00432-021-03602-w"
"34583091","Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma","Regmi P, Hu HJ, Lv TR, Paudyal A, Sah RB, Ma WJ, Jin YW, Li FY.","Surg Oncol. 2021 Dec;39:101663. doi: 10.1016/j.suronc.2021.101663. Epub 2021 Sep 24.","Regmi P","Surg Oncol","2021","2021/09/28","","","10.1016/j.suronc.2021.101663"
"34611833","The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation","Yilmaz S, Ince V.","J Gastrointest Cancer. 2021 Dec;52(4):1350-1355. doi: 10.1007/s12029-021-00716-9. Epub 2021 Oct 6.","Yilmaz S","J Gastrointest Cancer","2021","2021/10/06","","","10.1007/s12029-021-00716-9"
"34655179","Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis","Li Z, Li Q, Wang X, Chen W, Jin X, Liu X, Ye F, Dai Z, Zheng X, Li P, Sun C, Liu X, Zhang Q, Luo H, Liu R.","Cancer Med. 2021 Dec;10(23):8432-8450. doi: 10.1002/cam4.4350. Epub 2021 Oct 16.","Li Z","Cancer Med","2021","2021/10/16","PMC8633247","","10.1002/cam4.4350"
"34870682","Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis","Jácome AA, Castro ACG, Vasconcelos JPS, Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF, Gil RA, Prolla G, Garicochea B.","JAMA Netw Open. 2021 Dec 1;4(12):e2136128. doi: 10.1001/jamanetworkopen.2021.36128.","Jácome AA","JAMA Netw Open","2021","2021/12/06","PMC8649834","","10.1001/jamanetworkopen.2021.36128"
"34400801","Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers","Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J.","Br J Cancer. 2022 Jan;126(1):10-23. doi: 10.1038/s41416-021-01453-3. Epub 2021 Aug 16.","Zhou G","Br J Cancer","2022","2021/08/17","PMC8727557","","10.1038/s41416-021-01453-3"
"34796373","Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France","Garin E, Pinaquy JB, Bailly C, Sengel C, Mariano-Goulart D, Edeline J, Blanc JF, Bouvier A, Tordo J, Rode A, Becker S, Sefrioui D, de Baere T, Somma C, Mastier C, Goupil J, Chevallier P, Regnault H, Vibert E, Manfredi S, Vicaut E, Patel B, Boucher E, Guiu B; PROACTIF registry group.","Cardiovasc Intervent Radiol. 2022 Jan;45(1):1-11. doi: 10.1007/s00270-021-03002-0. Epub 2021 Nov 18.","Garin E","Cardiovasc Intervent Radiol","2022","2021/11/19","PMC9014840","","10.1007/s00270-021-03002-0"
"35418272","Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials","Zeng L, Su J, Qiu W, Jin X, Qiu Y, Yu W.","Cancer Control. 2022 Jan-Dec;29:10732748221092924. doi: 10.1177/10732748221092924.","Zeng L","Cancer Control","2022","2022/04/14","PMC9014721","","10.1177/10732748221092924"
"36155490","Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective","Duda DG.","Keio J Med. 2022;71(3):71. doi: 10.2302/kjm.71-004-ABST.","Duda DG","Keio J Med","2022","2022/09/26","","","10.2302/kjm.71-004-ABST"
"35109664","Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?","Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, Marco MD, Gadaleta-Caldarola G, Brandi G.","Future Oncol. 2022 Mar;18(8):1023-1034. doi: 10.2217/fon-2021-0905. Epub 2022 Feb 3.","Carloni R","Future Oncol","2022","2022/02/03","","","10.2217/fon-2021-0905"
"34774999","Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma","Sung W, Hong TS, Poznansky MC, Paganetti H, Grassberger C.","Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):1055-1062. doi: 10.1016/j.ijrobp.2021.11.008. Epub 2021 Nov 11.","Sung W","Int J Radiat Oncol Biol Phys","2022","2021/11/14","PMC9059476","NIHMS1756140","10.1016/j.ijrobp.2021.11.008"
"35346070","A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of (90)Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study","Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, Kappadath SC.","BMC Gastroenterol. 2022 Mar 28;22(1):151. doi: 10.1186/s12876-022-02204-1.","Mahvash A","BMC Gastroenterol","2022","2022/03/29","PMC8962126","","10.1186/s12876-022-02204-1"
"34429006","PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?","Rizzo A, Ricci AD.","Expert Opin Investig Drugs. 2022 Apr;31(4):415-423. doi: 10.1080/13543784.2021.1972969. Epub 2021 Aug 30.","Rizzo A","Expert Opin Investig Drugs","2022","2021/08/25","","","10.1080/13543784.2021.1972969"
"34853874","A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol","Fidelman N.","Cardiovasc Intervent Radiol. 2022 Apr;45(4):413-414. doi: 10.1007/s00270-021-03010-0. Epub 2021 Dec 1.","Fidelman N","Cardiovasc Intervent Radiol","2022","2021/12/02","","","10.1007/s00270-021-03010-0"
"35081747","Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol","Ben Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN.","Future Oncol. 2022 Apr;18(12):1423-1435. doi: 10.2217/fon-2021-1261. Epub 2022 Jan 27.","Ben Khaled N","Future Oncol","2022","2022/01/27","","","10.2217/fon-2021-1261"
"35396315","Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial","Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N.","BMJ Open. 2022 Apr 8;12(4):e059779. doi: 10.1136/bmjopen-2021-059779.","Ogasawara S","BMJ Open","2022","2022/04/09","PMC8995959","","10.1136/bmjopen-2021-059779"
"35190728","A framework for fibrolamellar carcinoma research and clinical trials","Dinh TA, Utria AF, Barry KC, Ma R, Abou-Alfa GK, Gordan JD, Jaffee EM, Scott JD, Zucman-Rossi J, O'Neill AF, Furth ME, Sethupathy P.","Nat Rev Gastroenterol Hepatol. 2022 May;19(5):328-342. doi: 10.1038/s41575-022-00580-3. Epub 2022 Feb 21.","Dinh TA","Nat Rev Gastroenterol Hepatol","2022","2022/02/22","PMC9516439","NIHMS1833772","10.1038/s41575-022-00580-3"
"35247922","Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials","Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX.","Clin Cancer Res. 2022 Jun 1;28(11):2297-2305. doi: 10.1158/1078-0432.CCR-21-4000.","Llovet JM","Clin Cancer Res","2022","2022/03/05","PMC9662930","","10.1158/1078-0432.CCR-21-4000"
"35287469","Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation","Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M.","Future Oncol. 2022 Jun;18(18):2173-2191. doi: 10.2217/fon-2021-1635. Epub 2022 Mar 15.","Azhie A","Future Oncol","2022","2022/03/15","","","10.2217/fon-2021-1635"
"35580650","Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021","Brown ZJ, Hewitt DB, Pawlik TM.","Expert Opin Investig Drugs. 2022 Jul;31(7):693-706. doi: 10.1080/13543784.2022.2079491. Epub 2022 May 26.","Brown ZJ","Expert Opin Investig Drugs","2022","2022/05/17","","","10.1080/13543784.2022.2079491"
"34780081","Changes in therapeutic options for hepatocellular carcinoma in Asia","Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N.","Liver Int. 2022 Aug;42(9):2055-2066. doi: 10.1111/liv.15101. Epub 2021 Nov 29.","Ogasawara S","Liver Int","2022","2021/11/15","","","10.1111/liv.15101"
"35107390","I-125 seeds insertion with TACE for advanced HCC: a meta-analysis of randomized controlled trials","Hou JP, Shi YB, Fu YF, Li H.","Minim Invasive Ther Allied Technol. 2022 Aug;31(6):848-855. doi: 10.1080/13645706.2022.2033786. Epub 2022 Feb 2.","Hou JP","Minim Invasive Ther Allied Technol","2022","2022/02/02","","","10.1080/13645706.2022.2033786"
"35545472","Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies","Wang P, Zhang D, Fang C, Gan Y, Luo B, Yang XL, Peng FY, Li B, Su S.","Eur J Surg Oncol. 2022 Aug;48(8):1685-1691. doi: 10.1016/j.ejso.2022.04.017. Epub 2022 Apr 29.","Wang P","Eur J Surg Oncol","2022","2022/05/11","","","10.1016/j.ejso.2022.04.017"
"35739268","Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y.","Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.","Zhu AX","Nat Med","2022","2022/06/23","","","10.1038/s41591-022-01868-2"
"34907081","Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies","Kudo M, Montal R, Finn RS, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, Llovet JM.","Clin Cancer Res. 2022 Aug 15;28(16):3443-3451. doi: 10.1158/1078-0432.CCR-21-3135.","Kudo M","Clin Cancer Res","2022","2021/12/15","","","10.1158/1078-0432.CCR-21-3135"
"35649228","Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?","Raphael MJ, Karanicolas PJ.","J Clin Oncol. 2022 Aug 20;40(24):2806-2817. doi: 10.1200/JCO.21.02505. Epub 2022 Jun 1.","Raphael MJ","J Clin Oncol","2022","2022/06/01","","","10.1200/JCO.21.02505"
"35968836","Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial","Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ.","Future Oncol. 2022 Sep;18(30):3367-3375. doi: 10.2217/fon-2022-0188. Epub 2022 Aug 15.","Wang K","Future Oncol","2022","2022/08/15","","","10.2217/fon-2022-0188"
"36115673","Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma","Zhang B, Yue J, Shi X, Cui K, Li L, Zhang C, Sun P, Zhong J, Li Z, Zhao L.","BMJ Open. 2022 Sep 17;12(9):e060955. doi: 10.1136/bmjopen-2022-060955.","Zhang B","BMJ Open","2022","2022/09/17","PMC9486305","","10.1136/bmjopen-2022-060955"
"36193490","Registered Trials of Artificial Intelligence Conducted on Chronic Liver Disease: A Cross-Sectional Study on ClinicalTrials.gov","Zheng G, Shi L, Liu J, Zhao Y, Du F, He Y, Yang X, Song N, Wen J, Gao H.","Dis Markers. 2022 Sep 20;2022:6847073. doi: 10.1155/2022/6847073. eCollection 2022.","Zheng G","Dis Markers","2022","2022/10/04","PMC9526577","","10.1155/2022/6847073"
"35785525","Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials","An J, Han S, Kim HI, Shim JH.","Hepatol Commun. 2022 Oct;6(10):2886-2900. doi: 10.1002/hep4.2025. Epub 2022 Jul 4.","An J","Hepatol Commun","2022","2022/07/05","PMC9512463","","10.1002/hep4.2025"
"35838903","Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses","Ilagan CH, Goldman DA, Gönen M, Aveson VG, Babicky M, Balachandran VP, Drebin JA, Jarnagin WR, Wei AC, Kingham TP, Abou-Alfa GK, Brown KT, D'Angelica MI.","Ann Surg Oncol. 2022 Oct;29(11):6815-6826. doi: 10.1245/s10434-022-12036-8. Epub 2022 Jul 15.","Ilagan CH","Ann Surg Oncol","2022","2022/07/15","PMC9509465","NIHMS1825730","10.1245/s10434-022-12036-8"
"35970037","Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials","Fulgenzi CAM, D'Alessio A, Airoldi C, Scotti L, Demirtas CO, Gennari A, Cortellini A, Pinato DJ.","Eur J Cancer. 2022 Oct;174:57-67. doi: 10.1016/j.ejca.2022.06.058. Epub 2022 Aug 12.","Fulgenzi CAM","Eur J Cancer","2022","2022/08/15","","","10.1016/j.ejca.2022.06.058"
"35998838","Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy","Wang L, Qiu L, Ke Q, Ji H, Wu J.","Radiother Oncol. 2022 Oct;175:101-111. doi: 10.1016/j.radonc.2022.08.019. Epub 2022 Aug 22.","Wang L","Radiother Oncol","2022","2022/08/23","","","10.1016/j.radonc.2022.08.019"
"36083440","Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease","Kong Y, Lv T, Li M, Zhao L, Meng T, Wu S, Wei W, Zhang Q, Chen S, You H, Lens S, Yoshiji H, Francque S, Tsochatzis E, Sarin SK, Mandorfer M, Jia J; BAVENO Cooperation: an EASL consortium.","Hepatol Int. 2022 Oct;16(5):1052-1063. doi: 10.1007/s12072-022-10369-w. Epub 2022 Sep 9.","Kong Y","Hepatol Int","2022","2022/09/09","","","10.1007/s12072-022-10369-w"
"36271374","Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis","Yang TK, Yu YF, Tsai CL, Li HJ, Yang PS, Huang KW, Cheng JC.","BMC Cancer. 2022 Oct 21;22(1):1085. doi: 10.1186/s12885-022-10174-6.","Yang TK","BMC Cancer","2022","2022/10/22","PMC9587661","","10.1186/s12885-022-10174-6"
"35906166","Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors","Stefanini B, Bucci L, Santi V, Reggidori N, Rampoldi D, Lani L, Granito A, Sangiovanni A, Cabibbo G, Farinati F, Campani C, Foschi FG, Svegliati-Baroni G, Raimondo G, Gasbarrini A, Mega A, Biasini E, Sacco R, Morisco F, Caturelli E, Vidili G, Azzaroli F, Giannini EG, Rapaccini GL, Brunetto MR, Masotto A, Nardone G, Di Marco M, Magalotti D, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.","Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003. Epub 2022 Jul 27.","Stefanini B","Dig Liver Dis","2022","2022/07/29","","","10.1016/j.dld.2022.07.003"
"36348422","The effect of mHealth-based exercise on Insulin Sensitivity for patients with Hepatocellular carcinoma and insulin resistance (mISH): protocol of a randomized controlled trial","Yeo SM, Oh JH, Yu HJ, Sinn DH, Hwang JH.","Trials. 2022 Nov 8;23(1):930. doi: 10.1186/s13063-022-06858-w.","Yeo SM","Trials","2022","2022/11/09","PMC9641912","","10.1186/s13063-022-06858-w"
"36367894","Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma","Mena E, Shih J, Chung JY, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-Moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL, Escorcia FE.","PLoS One. 2022 Nov 11;17(11):e0277407. doi: 10.1371/journal.pone.0277407. eCollection 2022.","Mena E","PLoS One","2022","2022/11/11","PMC9651549","","10.1371/journal.pone.0277407"
"36405383","Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy","Li SQ, Yang Y, Ye LS.","World J Gastroenterol. 2022 Nov 14;28(42):6034-6044. doi: 10.3748/wjg.v28.i42.6034.","Li SQ","World J Gastroenterol","2022","2022/11/21","PMC9669824","","10.3748/wjg.v28.i42.6034"
"36111952","Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis","Li Y, Liang X, Li H, Chen X.","Cancer. 2022 Nov 15;128(22):3995-4003. doi: 10.1002/cncr.34457. Epub 2022 Sep 16.","Li Y","Cancer","2022","2022/09/16","","","10.1002/cncr.34457"
"36410831","Adoptive immunotherapy with natural killer cells from peripheral blood CD34(+) stem cells to prevent hepatocellular carcinoma recurrence after curative hepatectomy: a study protocol for an open-label, single-arm phase I study","Ohira M, Kobayashi T, Tanaka Y, Imaoka Y, Sato K, Imaoka K, Nakano R, Doskali M, Piao J, Nakamura M, Yoshida T, Ichinohe T, Kawano R, Yoshimura K, Ueda K, Tamura N, Hirata T, Imamura M, Aikata H, Tanimine N, Kuroda S, Tahara H, Ide K, Ohdan H.","BMJ Open. 2022 Nov 21;12(11):e064526. doi: 10.1136/bmjopen-2022-064526.","Ohira M","BMJ Open","2022","2022/11/21","PMC9680173","","10.1136/bmjopen-2022-064526"
"36451456","Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma: A Review","Bu F, Yin S, Guan R, Xiao Y, Zeng S, Zhao Y.","Medicine (Baltimore). 2022 Nov 25;101(47):e31747. doi: 10.1097/MD.0000000000031747.","Bu F","Medicine (Baltimore)","2022","2022/12/01","PMC9704963","","10.1097/MD.0000000000031747"
"36912078","A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)","Mahmood S, Li D, Lee A, Rowe J, Beg M, Kasturi V, Iyer R, Abrams T, Dayyani F.","Future Oncol. 2022 Dec;18(40):4465-4471. doi: 10.2217/fon-2022-0844. Epub 2023 Mar 13.","Mahmood S","Future Oncol","2022","2023/03/13","","","10.2217/fon-2022-0844"
"36595779","Efficacy and safety of single- and multiple-antenna microwave ablation for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and network meta-analysis","Han Y, Zhao W, Wu M, Qian Y.","Medicine (Baltimore). 2022 Dec 23;101(51):e32304. doi: 10.1097/MD.0000000000032304.","Han Y","Medicine (Baltimore)","2022","2023/01/03","PMC9794220","","10.1097/MD.0000000000032304"
"36595979","Efficacy and safety of radiofrequency ablation and surgery for hepatocellular carcinoma in patients with cirrhosis: A meta-analysis","Zhang T, Hu H, Jia Y, Gao Y, Hao F, Wu J, Yang Z, Ren J, Li Z, Liu A, Wu H.","Medicine (Baltimore). 2022 Dec 30;101(52):e32470. doi: 10.1097/MD.0000000000032470.","Zhang T","Medicine (Baltimore)","2022","2023/01/03","PMC9803499","","10.1097/MD.0000000000032470"
"36473632","Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis","Hu L, Zheng Y, Lin J, Shi X, Wang A.","Clin Res Hepatol Gastroenterol. 2023 Jan;47(1):102061. doi: 10.1016/j.clinre.2022.102061. Epub 2022 Dec 5.","Hu L","Clin Res Hepatol Gastroenterol","2023","2022/12/06","","","10.1016/j.clinre.2022.102061"
"37557186","Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials","Zhang YL, Cui XJ, Xing H, Ning HF, Dong P, Wang GZ.","Ann Med. 2023;55(2):2242384. doi: 10.1080/07853890.2023.2242384.","Zhang YL","Ann Med","2023","2023/08/09","PMC10413926","","10.1080/07853890.2023.2242384"
"35993539","Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials","Liu X, Liu Q, Wu X, Yu W, Bao X.","Cancer Med. 2023 Feb;12(3):2238-2247. doi: 10.1002/cam4.5157. Epub 2022 Aug 22.","Liu X","Cancer Med","2023","2022/08/22","PMC9939089","","10.1002/cam4.5157"
"37097715","PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma","Fessas P, Scheiner B, D'Alessio A, M Fulgenzi CA, Korolewicz J, Ward C, Tait P, Thomas R, Cortellini A, Sharma R, Pinato DJ.","Future Oncol. 2023 Mar;19(7):499-507. doi: 10.2217/fon-2022-0916. Epub 2023 Apr 25.","Fessas P","Future Oncol","2023","2023/04/25","","","10.2217/fon-2022-0916"
"36978150","Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial","Lee SK, Yang H, Kwon JH, Shim DJ, Kim D, Nam SW, Yoo SH, Bae SH, Lee A, Lee YJ, Jeon C, Jang JW, Sung PS, Chun HJ, Kim SH, Choi JI, Oh JS, Yang YJ.","Trials. 2023 Mar 28;24(1):234. doi: 10.1186/s13063-023-07266-4.","Lee SK","Trials","2023","2023/03/28","PMC10045835","","10.1186/s13063-023-07266-4"
"36207763","Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis on intention-to-treat outcomes","Di Martino M, Ferraro D, Pisaniello D, Arenga G, Falaschi F, Terrone A, Maniscalco M, Galeota Lanza A, Esposito C, Vennarecci G.","J Hepatobiliary Pancreat Sci. 2023 Apr;30(4):429-438. doi: 10.1002/jhbp.1248. Epub 2022 Oct 22.","Di Martino M","J Hepatobiliary Pancreat Sci","2023","2022/10/07","","","10.1002/jhbp.1248"
"37226111","Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials","Huang D, Ke L, Cui H, Li S.","BMC Cancer. 2023 May 24;23(1):474. doi: 10.1186/s12885-023-10960-w.","Huang D","BMC Cancer","2023","2023/05/24","PMC10207853","","10.1186/s12885-023-10960-w"
"37280655","More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study","Momal R, Li H, Trichelair P, Blum MGB, Balazard F.","Trials. 2023 Jun 6;24(1):380. doi: 10.1186/s13063-023-07375-0.","Momal R","Trials","2023","2023/06/06","PMC10245605","","10.1186/s13063-023-07375-0"
"37345593","Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis","Pan D, Liu H, Ma X, Qu P, Cao M, Qin X, Tang J, Pan R, Huang Q, Han Z.","J Gastrointestin Liver Dis. 2023 Jun 22;32(2):222-229. doi: 10.15403/jgld-4729.","Pan D","J Gastrointestin Liver Dis","2023","2023/06/22","","","10.15403/jgld-4729"
"37162288","Systemic treatment in patients with Child-Pugh B liver dysfunction and advanced hepatocellular carcinoma","Costa F, Wiedenmann B, Roderburg C, Mohr R, Abou-Alfa GK.","Cancer Med. 2023 Jul;12(13):13978-13990. doi: 10.1002/cam4.6033. Epub 2023 May 10.","Costa F","Cancer Med","2023","2023/05/10","PMC10358256","","10.1002/cam4.6033"
"37627329","Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease","Kamata S, Honda A, Ishii I.","Biomolecules. 2023 Aug 18;13(8):1264. doi: 10.3390/biom13081264.","Kamata S","Biomolecules","2023","2023/08/26","PMC10452531","","10.3390/biom13081264"
"36781824","Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects","Fishman P, Stemmer SM, Bareket-Samish A, Silverman MH, Kerns WD.","Purinergic Signal. 2023 Sep;19(3):513-522. doi: 10.1007/s11302-023-09925-2. Epub 2023 Feb 13.","Fishman P","Purinergic Signal","2023","2023/02/13","PMC10539266","","10.1007/s11302-023-09925-2"
"37022089","Surgical Treatment of Hepatocellular Carcinoma: Multicenter Competing-risk Analysis of Tumor-related Death Following Liver Resection and Transplantation Under an Intention-to-treat Perspective","Di Sandro S, Sposito C, Ravaioli M, Lauterio A, Magistri P, Bongini M, Odaldi F, De Carlis R, Botta F, Centonze L, Maroni L, Citterio D, Guidetti C, Bagnardi V, De Carlis L, Cescon M, Mazzaferro V, Di Benedetto F; HV-HCC-MRT-group.","Transplantation. 2023 Sep 1;107(9):1965-1975. doi: 10.1097/TP.0000000000004593. Epub 2023 Aug 21.","Di Sandro S","Transplantation","2023","2023/04/06","","","10.1097/TP.0000000000004593"
"37406395","Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma","Shu Y, Tang Y, Ding Y, Zhang Q.","Int Immunopharmacol. 2023 Sep;122:110543. doi: 10.1016/j.intimp.2023.110543. Epub 2023 Jul 3.","Shu Y","Int Immunopharmacol","2023","2023/07/05","","","10.1016/j.intimp.2023.110543"
"37770273","Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol","Huang JT, Zhong JH, Zhang J, Gong WF, Ma L, Li LQ, Xiang BD.","BMJ Open. 2023 Sep 28;13(9):e067730. doi: 10.1136/bmjopen-2022-067730.","Huang JT","BMJ Open","2023","2023/09/28","PMC10546157","","10.1136/bmjopen-2022-067730"
"37772548","Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy","Yamamura K, Beppu T, Miyata T, Mima K, Okabe H, Nitta H, Imai K, Hayashi H, Oda E, Karashima R, Ozaki N, Isiko T.","Anticancer Res. 2023 Oct;43(10):4285-4293. doi: 10.21873/anticanres.16623.","Yamamura K","Anticancer Res","2023","2023/09/29","","","10.21873/anticanres.16623"
"37902128","The effectiveness of ablative and non-surgical therapies for early hepatocellular carcinoma: Systematic review and network meta-analysis of randomised controlled trials","South E, Wade R, Anwer S, Sharif-Hurst S, Harden M, Fulbright H, Dias S, Simmonds M, Rowe I, Thornton P, Wah TM, Eastwood A.","Cancer Med. 2023 Nov;12(22):20759-20772. doi: 10.1002/cam4.6643. Epub 2023 Oct 30.","South E","Cancer Med","2023","2023/10/30","PMC10709740","","10.1002/cam4.6643"
"38039047","Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid- to advanced stages of hepatocellular carcinoma - A systematic review and meta-analysis of randomized clinical trials","Li JF, Fu YX, Zhang HC, Ma H, Yuan GJ, Tan Y.","Eur Rev Med Pharmacol Sci. 2023 Nov;27(22):11156-11168. doi: 10.26355/eurrev_202311_34485.","Li JF","Eur Rev Med Pharmacol Sci","2023","2023/12/01","","","10.26355/eurrev_202311_34485"
"37290735","The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials","Chen J, Chen S, Luo H, Wu W, Wang S.","J Ethnopharmacol. 2023 Nov 15;316:116734. doi: 10.1016/j.jep.2023.116734. Epub 2023 Jun 7.","Chen J","J Ethnopharmacol","2023","2023/06/08","","","10.1016/j.jep.2023.116734"
"38037035","Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial","Huang Y, Xu L, Wang N, Pu X, Wang W, Wen T, Xu M, Jiang L.","Trials. 2023 Nov 30;24(1):774. doi: 10.1186/s13063-023-07820-0.","Huang Y","Trials","2023","2023/12/01","PMC10691107","","10.1186/s13063-023-07820-0"
"37300382","Analysis of individual patient data in patients with HCC treated with immunotherapy: A step forward for clinical trial design","Pinter M, Reig M, Cabibbo G.","Hepatology. 2023 Dec 1;78(6):1684-1687. doi: 10.1097/HEP.0000000000000511. Epub 2023 Jun 12.","Pinter M","Hepatology","2023","2023/06/10","","","10.1097/HEP.0000000000000511"
"38149643","Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis","Wade R, South E, Anwer S, Sharif-Hurst S, Harden M, Fulbright H, Hodgson R, Dias S, Simmonds M, Rowe I, Thornton P, Eastwood A.","Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.","Wade R","Health Technol Assess","2023","2023/12/27","PMC11017143","","10.3310/GK5221"
"38042834","The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial","Peng W, Yi M, Qi X, Qi W, Li C, Wen T.","Trials. 2023 Dec 2;24(1):781. doi: 10.1186/s13063-023-07822-y.","Peng W","Trials","2023","2023/12/02","PMC10693690","","10.1186/s13063-023-07822-y"
"38190815","Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Pei X, Zhao J, Wang Z.","Oncology. 2024;102(8):688-702. doi: 10.1159/000536006. Epub 2024 Jan 8.","Pei X","Oncology","2024","2024/01/08","","","10.1159/000536006"
"38218177","The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma","D'Alessio A, Rimassa L.","Med. 2024 Jan 12;5(1):7-9. doi: 10.1016/j.medj.2023.11.004.","D'Alessio A","Med","2024","2024/01/13","","","10.1016/j.medj.2023.11.004"
"38313229","Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis","Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX.","World J Gastroenterol. 2024 Jan 28;30(4):318-331. doi: 10.3748/wjg.v30.i4.318.","Cao YZ","World J Gastroenterol","2024","2024/02/05","PMC10835538","","10.3748/wjg.v30.i4.318"
"38367972","Study protocol for FASTRAK: a randomised controlled trial evaluating the cost impact and effectiveness of FAST-MRI for HCC suRveillance in pAtients with high risK of liver cancer","Nahon P, Ronot M, Sutter O, Natella PA, Baloul S, Durand-Zaleski I, Audureau E.","BMJ Open. 2024 Feb 17;14(2):e083701. doi: 10.1136/bmjopen-2023-083701.","Nahon P","BMJ Open","2024","2024/02/17","PMC10875554","","10.1136/bmjopen-2023-083701"
"38369480","Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies","Hu L, Lin J, Wang A, Shi X, Qiao Y.","World J Surg Oncol. 2024 Feb 19;22(1):56. doi: 10.1186/s12957-024-03330-8.","Hu L","World J Surg Oncol","2024","2024/02/18","PMC10875898","","10.1186/s12957-024-03330-8"
"38388861","Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study","Wang K, Cui H, Zhu Y, Hu X, Hong C, Guo Y, An L, Zhang Q, Liu L.","BMC Cancer. 2024 Feb 22;24(1):246. doi: 10.1186/s12885-024-11959-7.","Wang K","BMC Cancer","2024","2024/02/22","PMC10885498","","10.1186/s12885-024-11959-7"
"38395854","Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma","Jin Y, Ren H, Yue Q, Wu W, Liu C, Guo Y, Zhao P.","BMC Cancer. 2024 Feb 23;24(1):258. doi: 10.1186/s12885-024-12000-7.","Jin Y","BMC Cancer","2024","2024/02/23","PMC10893652","","10.1186/s12885-024-12000-7"
"37973531","Effects of enhance recovery after surgery nursing program on the surgical site wound infection in patients undergoing laparoscopic hepatectomy for hepatocellular carcinoma: A meta-analysis","Liu L, Zhang M, Zhang X, Xiang Q.","Int Wound J. 2024 Mar;21(3):e14490. doi: 10.1111/iwj.14490. Epub 2023 Nov 16.","Liu L","Int Wound J","2024","2023/11/16","PMC10898384","","10.1111/iwj.14490"
"38147153","Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial","Choi JW, Kim HC, Han J, Jang MJ, Chung JW.","Cardiovasc Intervent Radiol. 2024 Mar;47(3):372-378. doi: 10.1007/s00270-023-03621-9. Epub 2023 Dec 26.","Choi JW","Cardiovasc Intervent Radiol","2024","2023/12/26","","","10.1007/s00270-023-03621-9"
"38181120","A commentary on 'Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: a randomised controlled trial'","Li O, Ou C, Zhang H, Liu Y.","Int J Surg. 2024 Mar 1;110(3):1860-1861. doi: 10.1097/JS9.0000000000001015.","Li O","Int J Surg","2024","2024/01/05","PMC10942151","","10.1097/JS9.0000000000001015"
"38231887","Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial-level analysis","Colloca GA, Venturino A.","Cancer. 2024 May 15;130(10):1773-1783. doi: 10.1002/cncr.35199. Epub 2024 Jan 17.","Colloca GA","Cancer","2024","2024/01/17","","","10.1002/cncr.35199"
"38502889","Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update","Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG.","J Clin Oncol. 2024 May 20;42(15):1830-1850. doi: 10.1200/JCO.23.02745. Epub 2024 Mar 19.","Gordan JD","J Clin Oncol","2024","2024/03/19","","","10.1200/JCO.23.02745"
"35988688","Interventional radiology meets immuno-oncology for hepatocellular carcinoma","Salem R, Greten TF.","J Hepatol. 2024 Jun;80(6):967-976. doi: 10.1016/j.jhep.2022.08.003. Epub 2022 Aug 19.","Salem R","J Hepatol","2024","2022/08/21","","","10.1016/j.jhep.2022.08.003"
"37399245","Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology","Iavarone M, Nault JC, Cabibbo G, Torres F, Reig M.","Hepatology. 2024 Jun 1;79(6):1452-1462. doi: 10.1097/HEP.0000000000000527. Epub 2023 Jul 3.","Iavarone M","Hepatology","2024","2023/07/03","PMC11095876","","10.1097/HEP.0000000000000527"
"37638472","Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers: A Retrospective Study and Meta-analysis","Imamura T, Ohgi K, Mori K, Ashida R, Yamada M, Otsuka S, Uesaka K, Sugiura T.","Ann Surg. 2024 Jun 1;279(6):1025-1035. doi: 10.1097/SLA.0000000000006084. Epub 2023 Aug 28.","Imamura T","Ann Surg","2024","2023/08/28","","","10.1097/SLA.0000000000006084"
"38307346","Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice","Cabibbo G, Celsa C, Rimassa L, Torres F, Rimola J, Kloeckner R, Bruix J, Cammà C, Reig M.","J Hepatol. 2024 Jun;80(6):957-966. doi: 10.1016/j.jhep.2024.01.018. Epub 2024 Feb 1.","Cabibbo G","J Hepatol","2024","2024/02/02","","","10.1016/j.jhep.2024.01.018"
"38573077","A commentary on 'Neoadjuvant intensity modulated radiotherapy for a single and small (≤5 cm) hepatitis B virus-related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial'","He T, Zou J, Sun K.","Int J Surg. 2024 Jun 1;110(6):3966-3967. doi: 10.1097/JS9.0000000000001252.","He T","Int J Surg","2024","2024/04/04","PMC11175812","","10.1097/JS9.0000000000001252"
"38711357","Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply","Mohr R, Tacke F, Roderburg C.","Aliment Pharmacol Ther. 2024 Jun;59(11):1465-1466. doi: 10.1111/apt.18008.","Mohr R","Aliment Pharmacol Ther","2024","2024/05/07","","","10.1111/apt.18008"
"38837373","Gene therapy for people with hepatocellular carcinoma","Naing C, Ni H, Aung HH, Htet NH, Nikolova D.","Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013731. doi: 10.1002/14651858.CD013731.pub2.","Naing C","Cochrane Database Syst Rev","2024","2024/06/05","PMC11152182","","10.1002/14651858.CD013731.pub2"
"38849765","Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails","Wang G, Zhang J, Liu H, Zheng Q, Sun P.","BMC Gastroenterol. 2024 Jun 7;24(1):195. doi: 10.1186/s12876-024-03282-z.","Wang G","BMC Gastroenterol","2024","2024/06/07","PMC11162027","","10.1186/s12876-024-03282-z"
"38858156","Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial","Zhang J, Yang Y, Wu Z, Zhang S, Lin Z, Liu H, Hu J, Zhang T, Tang J, Xue J.","BMJ Open. 2024 Jun 10;14(6):e077903. doi: 10.1136/bmjopen-2023-077903.","Zhang J","BMJ Open","2024","2024/06/10","PMC11168160","","10.1136/bmjopen-2023-077903"
"38748333","Does an Aspirin a Day Take the MASLD Away?","Lonardo A, Zheng MH.","Adv Ther. 2024 Jul;41(7):2559-2575. doi: 10.1007/s12325-024-02885-y. Epub 2024 May 15.","Lonardo A","Adv Ther","2024","2024/05/15","","","10.1007/s12325-024-02885-y"
"39016316","Comment on: Laparoscopic liver resection versus radiofrequency ablation for small hepatocellular carcinoma: randomized clinical trial","Bahri S, Brown L, Perin G, Balasubramanian SP.","Br J Surg. 2024 Jul 2;111(7):znae171. doi: 10.1093/bjs/znae171.","Bahri S","Br J Surg","2024","2024/07/17","","","10.1093/bjs/znae171"
"38973009","A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)","Wigg A, Tibballs J, Woodman R, Stuart K, Le H, Roberts SK, Olynyk JK, Strasser SI, Wallace M, Martin J, Haworth A, Hardcastle N, Loo KF, Tang C, Lee YY, Chu J, De Abreu Lourenco R, Koukourou A, De Boo D, McLean K, Buck J, Sawhney R, Nicoll A, Dev A, Wood M, Braund A, Weltman M, Khor R, Levy M, Wang T, Potter M, Haridy J, Raj A, Duncan O, Zekry A, Collier N, O'Beirne J, Holliday C, Trada Y, Tronidjaja J, George J, Pryor D.","BMC Cancer. 2024 Jul 8;24(1):813. doi: 10.1186/s12885-024-12504-2.","Wigg A","BMC Cancer","2024","2024/07/07","PMC11229272","","10.1186/s12885-024-12504-2"
"39030637","Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial","Hao Y, Xie F, Zhou Y, Li C, Zhang X, Shen J, Yao M, Sun X, Zhou J, Wen T, Peng W.","Trials. 2024 Jul 19;25(1):490. doi: 10.1186/s13063-024-08340-1.","Hao Y","Trials","2024","2024/07/19","PMC11264851","","10.1186/s13063-024-08340-1"
"38803056","Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Payo-Serafín T, Méndez-Blanco C, Fernández-Palanca P, Martínez-Geijo J, Reviejo M, Ortiz-de-Urbina JJ, González-Gallego J, Marin JJG, Mauriz JL, San-Miguel B.","Clin Pharmacol Ther. 2024 Aug;116(2):328-345. doi: 10.1002/cpt.3312. Epub 2024 May 27.","Payo-Serafín T","Clin Pharmacol Ther","2024","2024/05/28","","","10.1002/cpt.3312"
"39039690","Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents","Amadeo E, Foti S, Camera S, Rossari F, Persano M, Lo Prinzi F, Vitiello F, Casadei-Gardini A, Rimini M.","Expert Opin Investig Drugs. 2024 Aug;33(8):839-849. doi: 10.1080/13543784.2024.2377321. Epub 2024 Jul 22.","Amadeo E","Expert Opin Investig Drugs","2024","2024/07/23","","","10.1080/13543784.2024.2377321"
